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ABSTRACT
Cellular-based Brain Pathology in the Anterior Cingulate Cortex of Males with
Autism Spectrum Disorder
by
Jessica D. Crawford
Autism spectrum disorder (ASD) now affects 1 in 68 children in the United States.
Disorders within this spectrum share hallmark deficits in verbal and nonverbal
communication, repetitive behavior, and social interaction. The cause of ASD is still
unknown. Even though hundreds of genetic abnormalities have been identified in ASD,
these markers account for less than 1% of all ASD cases. Researchers continue to
search for pathological markers common to all or most cases of ASD. The research
presented in this dissertation used a novel combination of state-of-the-art methods to
investigate brain pathology in ASD. Postmortem anterior cingulate cortex (ACC) from
ASD and typically developing brain donors was obtained from 2 national brain banks.
The ACC was chosen for study because of its documented role in influencing behaviors
characteristically disrupted in ASD. An initial study revealed elevated glial fibrillary
acidic protein (GFAP) in ACC white matter from ASD brain donors compared to typically
developing control donors. Laser capture microdissection was then employed to isolate
specific cell populations from the ACC from ASD and control brain donors. Captured
cells were used to interrogate potential gene expression abnormalities that may underlie
biological mechanisms that contribute behavioral abnormalities of ASD. The expression
of 4 genes associated with synaptic function, NTRK2, GRM8, SLC1A1, and GRIP1,
were found to be significantly lower in ACC pyramidal neurons from ASD donors when
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compared to control donors. These expression abnormalities were not observed in
ACC glia. Given robust evidence of neuronal and glial pathology in the ACC in ASD, a
novel method for whole transcriptome analysis in single cell populations was developed
to permit an unbiased analysis of brain cellular pathology in ASD. A list of genes that
were differentially expressed, comparing ASD to control donors, was produced for both
white matter and pyramidal neuron samples. By examining the ASD brain at the level of
its most basic component, the cell, methods were developed that should allow future
research to identify common cellular-based pathology of the ASD brain. Such research
will increase the likelihood of future development of novel pharmacotherapy for ASD
patients.
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CHAPTER 1
INTRODUCTION

Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a collection of development disorders that
affect social interaction, verbal and nonverbal communication, and repetitive behaviors.
Based on new diagnostic guidelines released in the Diagnostic and Statistical Manual of
Mental Disorders V (DSM-V) (American Psychiatric Association, 2013), the spectrum
now includes autistic disorder, pervasive developmental disorder not otherwise
specified (PDD-NOS), and Asperger’s syndrome. The world prevalence of ASD is 1%
(Kim et al., 2011). Children with ASD can be found in countries throughout the world,
but the greatest number of affected individuals occurs in the United States. There has
been a 78% increase in the number of ASD cases since 2002. The disorder now
affects 1 in 68 in the United States with a male to female ratio of 5:1 (Baio, 2014). A
more age-targeted report from the Centers for Disease Control (CDC) found that as
many as 1 in 50 school-age children in the United States could be affected (Blumberg et
al., 2013).
With the worldwide increase in the number of cases per year, many countries
including the United States and France have designated this disorder as a national
concern and in response have increased funds for services and research. Currently
ASD is costing the United States $250 billion per year (Buescher, Cidav, Knapp, &
Mandell, 2014). Despite the increase in awareness and efforts to impede the rise in this
disorder, the social burden will only grow in the coming years. In the next 10 years it is
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projected that the cost for the United States could reach $400 billion per year (Buescher
et al., 2014). In additional to the cost associated with caring for any child, families of
ASD individuals will spend an addition $35,000 per year for care and services (Horlin,
Falkmer, Parsons, Albrecht, & Falkmer, 2014). This cost typically increases after age
18 when school-related services end. The root of cost stems from the nature of the
disorder. ASD is diagnosed very early in life and is a life-long disorder. It does not
change the life expectancy of individuals meaning that services are need for 60 plus
years. Other comorbidities, especially intellectual disabilities, only add to the cost and
amount of services needed for the individual. The fact that no effective treatments exist
to prevent, slow the progress, or cure this disorder increases the urgency for
understanding the pathobiological development and progression of this disease.

Diagnostic Methods
Due to the nature of a spectrum disorder, the presentation of signs and
symptoms is extremely heterogeneous throughout the population. Researchers and
clinicians believe that the broad variability in ASD presentation might shed light on the
etiology of the disorder, which has yet to be discovered. However, the lack of
information about the pathophysiology of ASD translates to a purely behavioral
diagnosis. The most common diagnostic technique employs a standardized
assessment called the Autism Diagnostic Interview Revised (ADI-R) (Le Couteur,
Haden, Hammal, & McConachie, 2008). Children are generally diagnosed around 18
months to 2 years of age. Due to a push for early intervention, emerging diagnostic
tests have allowed for a diagnosis to be made prior to a child’s second birthday based
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on review of home videos and parental reporting (Adrien et al., 1991, 1992; Baranek,
1999; Maestro, Casella, Milone, Muratori, & Palacio-Espasa, 1999; Mars, Mauk, &
Dowrick, 1998; Massie, 1978; Osterling & Dawson, 1994; Rosenthal, Massie, & Wulff,
1980; Werner, Dawson, Osterling, & Dinno, 2000; Zakian, Malvy, Desombre, Roux, &
Lenoir, 2000; Zwaigenbaum et al., 2005). Early intervention is one of the top concerns
for clinicians. It is a well-accepted theory that the earlier behavioral therapy and
intervention can take place in a patient’s life, the better the overall prognosis will be for
that individual. Individuals are more likely to live independently and be employed as
adults. In addition to a better outcome, the cost of lifetime care and services can be
reduced by as much as two thirds if intervention is started early (Buescher et al., 2014).

Current Treatments
Current treatment paradigms include drugs that offer symptomatic relief paired
with behavioral modification therapy. Currently there are only two drugs that have been
approved by the Food and Drug Administration (FDA) for the treatment of behaviors
associated with ASD. These drugs are the atypical antipsychotics risperidone and
aripiprazole, which are approved to treat irritability in 6-17 year old children with ASD
(Blankenship, Erickson, Stigler, Posey, & McDougle, 2010; Kirino, 2012; Wink,
Erickson, & McDougle, 2010). Despite the wide use of these drugs in the ASD patient
population, they are not targeted at the core symptoms of ASD. Many drugs, including
antidepressants and anticonvulsants, are prescribed for “off-label” use in hopes of
managing other aspects of the disease such as hyperactive and self-harming behaviors
or common comorbidities (Lofthouse, Hendren, Hurt, Arnold, & Butter, 2012).
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Despite the emphasis on the core behavioral deficits, physiological symptoms
are also present. ASD patients display symptoms ranging from seizures to
gastrointestinal abnormalities (Kral, Eriksen, Souders, & Pinto-Martin, 2013; Robinson,
2012). Due to the lack of treatment options available, many parents have turned to
alternative medicines and treatments such as dietary restriction or various vitamin
regimens in hopes of alleviating symptoms (Levenson, 2013; Lofthouse et al., 2012).
One of the most popular of these treatments remains the gluten-free, casein-free diet
(Whiteley et al., 2012). The popularity of this treatment still holds despite reports that it
has no effect of the symptoms of ASD (Marí-Bauset, Zazpe, Mari-Sanchis, LlopisGonzález, & Morales-Suárez-Varela, 2014). Because reasonable treatment options are
not available to significantly enhance outcomes, reverse the disease, or arrest its
progress, parents and clinicians are turning to treatment options that do little to improve
the quality of life for these patients. Sadly, these nonevidence based and alternative
treatments increase the cost of the disorder in the face of little benefit to the ASD
patient.

Etiology of ASD
As discussed above, there are no effective treatments for ASD mainly due to the
lack of an identifiable cause. The increase in research over the last decade has
produced many clues to guide researchers. As with any spectrum disorder, it could be
hypothesized that the heterogeneity of symptom presentation could represent different
underlying causes. For ASD these causes can be divided into three categories. There
are a percentage of ASD cases that can be linked to other neurological disorders such
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as tuberous sclerosis (Barton & Volkmar, 1998; Wassink, Brzustowicz, Bartlett, &
Szatmari, 2004). Chromosomal abnormalities can also account for a small percentage
of ASD cases (Bruining et al., 2014; Devlin & Scherer, 2012; Konstantareas &
Homatidis, 1999; Liao et al., 2013). However, these associations with ASD only
account for about 10% of the population of ASD patients. The remaining 90% of cases,
which are categorized as idiopathic autism, have an unknown origin. A variety of
factors including environmental exposures and genetic abnormalities have been linked
to idiopathic autism (Blake, Hoyme, & Crotwell, 2013).

Role of Genetics
A vast amount of the current research in ASD is based on patient genetics.
Research on the genetics of ASD has identified over 100 mutations thought to
contribute to the development of ASD (Betancur, 2011). These mutations include
chromosomal alterations, copy number variations, and single gene mutations. Some of
the major mutated genes of interest that are worth noting are PTEN, the SHANK family,
and the NLGN family. The majority of these genes are neurological based with a great
number of them encoding synapse-related proteins. Some of these known gene and
chromosomal mutations also play a role in other neuropsychiatric and autism-related
disorders where the genetic based etiology of the disease is more certain, such as
Fragile X and Angelmann syndromes. A unifying genetic or biochemical basis of ASD
might be hard to elucidate due to the prevalence of comorbidities in ASD patients. In
this patient population 70% of individuals have at least one other diagnosed psychiatric
disorder with over 40% have two or more comorbid disorders (Simonoff et al., 2008).
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The identification and treatment of these other disorders are so essential that diagnostic
tools have been developed to screen for these psychiatric disorders with the presence
of ASD behavioral symptoms (Leyfer et al., 2006; Leyfer, Tager-Flusberg, Dowd,
Tomblin, & Folstein, 2008).
Regardless of the complexity of the disorder, there is little doubt that genetics
play a role in the etiology of autism, but there is equal evidence to show that genetics is
not the only factor. The strongest evidence comes from twin studies of autism
concordance. Twin studies show that genes play some role in the development of the
disease but are not the only factors at work. The prevalence of ASD among
monozygotic twins is 35% to 90% (Ronald & Hoekstra, 2011). However, as a spectrum
disorder symptoms are highly variable even between monozygotic twins resulting in
differential placement on the ASD spectrum. These findings suggest that environmental
factors affect underlying genetic variation to promote ASD onset.
One of the most recent twin studies was performed on a population in California
in 2011. Based of the findings of this study, gene mutations are likely to account for
roughly 55% of the cases of autism (Hallmayer et al., 2011). This is much lower than
previously reported rates. There are several possible reasons for the outcome of this
study. One is the inclusion of a boarder population of twins that represented a variety of
socioeconomic groups. Most previous twin studies were on smaller, more homogenous
populations. Another reason affecting the lower gene contribution to ASD risk could be
related to changes in diagnostic criteria over time. By 2011 the DSM IV was using the
spectrum-based diagnostic criteria. Moving forward with the newest diagnostic criteria
release in the DSM V, this study best describes the current population of ASD patients.
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However, with only half of the cases of idiopathic ASD accounted for, researchers must
look to other factors to fully understand this group of disorders.

Environmental Factors
An increase in the human ingestion of synthetic chemicals and compounds has
paralleled the increase in ASD rates. Both pregnant women and children are being
exposed to these chemicals on a daily basis and strikingly only a small percentage have
been researched to determine what potential harmful effects could be produced in
susceptible populations. Because gene mutations only account for some of the cases
of ASD, researchers are also interested in the role of environmental factors in the
pathology of ASD. These factors not only include the outdoor environment such as
external pollutants and heavy metals (Bjorklund, 2013) but also prenatal environmental
factors such as maternal antibodies, infection, and inflammation.
There has been a controversial debate about the link between autism and
vaccines. In the late 1990s the issue first received attention after a publication in the
Lancet claimed that the measles-mumps-rubella (MMR) vaccination could cause autism
(Wakefield et al., 1998). The number of parents vaccinating their children dropped in
response to the article. Even though the article was later retracted due to falsified data,
the issue is still debated and the number of children receiving vaccinations is still down.
Since the initial publication, researchers have been trying to reassure the public about
the safety and positive benefits of vaccinating children (Godlee, Smith, & Marcovitch,
2011; Savoy, 2014; Taylor, Swerdfeger, & Eslick, 2014).
ASD is considered a developmental disease because symptoms emerge at the
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same time the brain is undergoing major growth and changes. Researchers have been
trying to identify at what point (prenatal or postnatal) development is affected and ASD
occurs. There is strong evidence to suggest that a maternal infection or an active
immune response during pregnancy increases the chance of delivering a child with ASD
(Lee et al., 2014; Zerbo et al., 2013). Maternal antibodies and other diffusible factors of
the immune response cross the placenta and may alter the undeveloped immune
system of the fetus (Poletaev et al., 2014). Some of these antibodies have been
classified as anti-brain and are associated with severe cognitive dysfunction (Piras et
al., 2014).
Maternal antibodies are not the only substances that can cross the placental
barrier. There is also evidence that the medications used during pregnancy can
increase the risk of ASD. Not all prescription drug use is associated with ASD. Drugs
such as steroids and cardiovascular drugs were not found to increase the risk of ASD in
children (Gardener, Spiegelman, & Buka, 2009). The largest risk is linked to the use of
psychoactive drugs, in particular antidepressants (Gidaya et al., 2014; Harrington, Lee,
Crum, Zimmerman, & Hertz-Picciotto, 2013). More research is needed to see the
effects of these drugs in a larger population and determine if the mother’s need for
treatment outweighs the risk to the child.

Brain Pathology
Despite autism first being observed in 1940s (Kanner, 1943), it was not until the
1980s that researchers started to uncover the underlying neuropathology. One of the
first anatomical features of ASD to be noted was an increase in head size. Brain

20	
  

	
  
imaging data supports that a similar increase in brain growth occurs in 90% of autistic
males under the age of 4 (Courchesne et al., 2001). It is not clearly understood if this
overall increase in brain size remains through adulthood. This is mostly due to the lack
of adult population studies. To date, there have not been any reliable correlations found
between an increase in brain size and key behavioral traits associated with ASD. With
the advent of new imaging technologies that allow for the division of specific brain
structure volumes to be measure separately, behavior specific correlation could begin to
be discovered with focus on the regions thought to modulate those behaviors.
The brain consists of two matter types. Gray matter is comprised of the neuronal
cell bodies and various glial cell types including protoplasmic astrocytes,
oligodendrocytes, and microglia. As the neuronal axons leave the gray matter to make
connections to other brain areas, the axons pass into white matter. Within white matter,
the axons are covered by oligodendrocytes creating the myelin sheath and supported
by other glial cell types including fibrous astrocytes and microglia. Brain imaging
studies have found that these two matter types do not undergo the same growth pattern
in the ASD brain. Evidence suggests that white matter show a greater enlargement in
the ASD brain during early childhood than gray matter (Courchesne et al., 2001; Hazlett
et al., 2005; Herbert et al., 2003). However, gray matter overgrowth changes have
been found to last into adulthood, whereas white matter alterations are transient and
only seen in young children (Hazlett, Poe, Gerig, Smith, & Piven, 2006).
The white and gray matter changes mentioned above are most likely the result of
underlying cellular changes. The variation in growth pattern between the two matter
types could be attributed to the differing cell populations in each matter type. Within the
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cortical gray matter, there are microstructural changes observed in the ASD brain.
Cortical tissue contains a vast amount of minicolumns, which are functional units that
contain both excitatory and inhibitory neurons working together to maintain brain
homeostasis. In the ASD brain there is an imbalance in these minicolumns due to
disruptions in the inhibitory force (Casanova, Buxhoeveden, Switala, & Roy, 2002;
Casanova & Trippe, 2009). Cellular dysfunction has also been noted in white matter
where an excess of interstitial space has been attributed to the pathology of a yet
unknown cell type found in white matter (Groen, Buitelaar, van der Gaag, & Zwiers,
2011).

Methods for Researching ASD Pathology
In addition to the genetics data produced by using patient’s blood samples
discussed above, the other main research methodologies used to study ASD are brain
imaging in living subjects, modeling ASD using laboratory animals, and pathology
studies using human postmortem tissue from ASD brain donors. Each of these
methods provides unique information to our understanding of ASD. A relatively recent
introduction of animal models and patient tissue samples into ASD research has
opened the door to the application of molecular and cellular techniques to determine the
underlying pathology of ASD. Brain imaging was discussed in a previous section in
regards to brain structure studies. The other two methodologies are reviewed below.

Animal Models of ASD
In the efforts to create a dynamic model of the disorder researchers have turned
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to animal models. A wealth of genetic data already exists from ASD patients that
provide numerous genes of interests for the creation of models. One downside to this
approach is the hypothesis that it takes several gene abnormalities occurring together in
order to produced the disease. When researchers create a knockout mouse for one of
the major genes associated with ASD, the animal only presents with one or two of the
behavioral core symptoms but not all three of them. Even though these animals are not
used for comprehensive studies of ASD, the models have produced information about
what genes are important for specific behaviors and brain development. For example,
the PTEN knockout mouse shows deficits in social interaction and an increase in
repetitive behavior but shows no change in communication. However, these changes
seems to be associated with alternation of synaptic signaling (Lugo et al., 2014).
Another criticism of current animal models is the lack of anatomical pathology.
The disorder is diagnosis solely on behavior and the current models do well in modeling
the behavioral features of autism. Most validation studies for these models do not
examine the underlying brain pathology along with behavior. Those studies that have
taken the step to include anatomical validation have yielded very few models that show
the brain abnormalities seen in patients with autism.
The mouse model that has been most accepted and researched in regards to
ASD is the BTBR T+tf/J mouse. This mouse is an inbred strain that exhibits all three of
the hallmark behaviors of ASD. These behavioral traits have been tested using multiple
behavioral methods for the measurement of social interaction, communication, and
repetitive behaviors (Bolivar, Walters, & Phoenix, 2007; McFarlane et al., 2008; Meyza
et al., 2012). This model also displays neuroanatomical changes as well. Some of the
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more notable brain changes are the absence of the corpus callosum and size alteration
in the hippocampus. These structural changes have been found in a small number of
ASD patients but are not widespread in the population. This model was created using a
forward genetic model system where researchers create a model that exhibits the
characteristics of a disorder and then find the genes responsible for the changes. This
could prove to be a better approach than reverse genetic model creation because
multiple gene abnormalities are required for ASD to occur.

Use of Postmortem Tissue in ASD Research
The use of postmortem brain tissue from autistic donors allows researchers to
interrogate molecular and cellular pathology underlying brain abnormalities discovered
using in vivo imaging techniques. However, there are several limitations to the use of
postmortem tissue as there is with any research methodology. A large downside is the
variation found in human subject studies. Unlike animal or cell culture models, subject
to subject variability is a consideration that has to be taken into account during the
planning phase of any postmortem experiment or project. Factors such as tissue
quality, age, sex, postmortem interval time, medical history, and toxicology could
influence findings. In the studies presented here our lab has controlled for as many of
these factors as was possible by matching control and ASD cases by the potentially
confounding variable. For those variables that could not be matched across control and
ASD cases, statistical methods were used to evaluate the potential effect of the variable
on experimental outcomes.
Another limitation is the static nature of a tissue sample. Postmortem tissue
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allows for the investigation of a disease state at one time point. This type of sample
lends itself well to studies designed to measure expression levels of various genes and
proteins or even structural and morphometric analysis. However, the tissue sample
cannot be manipulated biochemically to investigate mechanisms by which pathology is
initiated or induced. Once data are collected from postmortem tissue, the research
approach must then move to an appropriate model of the disease that allows for a
dynamic environment, i.e. reverse translational research.
Despite the drawbacks of human postmortem brain research, the use of these
tissues allows for a detailed examination of the biological and molecular processes
associated with the disease state in the human subject. In an editorial from Autism
Research, the official journal of the International Society for Autism Research, the
editor-in-chief. Anthony Bailey addressed the need for ASD research using postmortem
tissues stating that the field could only move forward by uncovering the molecular
pathology that postmortem tissue can provide (Bailey, 2008). A growing group of ASD
researchers agree with. Bailey’s understanding of the importance of postmortem
studies. This has prompted the worldwide campaign, It Takes Brains, to increase brain
donations and provide support for postmortem researchers. Even with the increased
interest in ASD postmortem research, the field is still alarmingly behind that of other
brain disorders. Not only are there a small number of ASD brains available, but proper
typically developing age matched controls are also needed. Typically developing
controls are defined as individuals who do not have any diagnosis classified as a
developmental disorder as well as other diagnosed medical disorders. These controls
are important because they allow for the comparison of brain pathology in the presence
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and absence of ASD at a given age point.
The use of ASD postmortem tissue has so far been limited to stereology and
homogenate sample-based protein studies. While these studies have been paramount
in introducing the use of postmortem tissue into ASD research, the resolution of these
experiments has not been high enough to truly identify underlying molecular pathways
or cellular changes associated with ASD. The brain is a very complex organ made up
of highly specialized areas communicating within and between each other to function
properly. At the core of this organization are numerous cell types that play a role in this
overall structure and function. Currently, ASD postmortem studies have focused on
these areas as whole entities despite the underlying cellular complexity. This could be
one reason that past postmortem studies have done little in the way of producing
answers about the cellular basis of ASD.

Overview of Experiments
This dissertation presents a set of studies that systematically increase the
resolution of analysis of ASD pathology, i.e. interrogating potential gene expression
abnormalities in specific brain regions, brain matter types, and then cell types. By
combining both molecular approaches and postmortem brain tissue, a better
understanding of pathology should be achieved. My research was focused specifically
on ASD brain pathology, but the methods used could be applied to study any
neurological or psychiatric disease. The pathways and genes found to be altered in
these studies could also serve as a starting point for the investigation of other diseases
or could be employed in animal models using transgenic technology.
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Chapter 2 begins with the investigation of cell specific protein markers within gray
and white matter regions of Brodmann area 24 (BA24) and Brodmann area 10 (BA10).
As discussed above, ASD postmortem brain research had not investigated brain
pathology within a specific brain region at a tissue or cellular level. By simply dividing
the brain regions by the matter types (white versus gray), we start to reduce the number
of different cell types present in the experimental sample. This study directed my single
cell studies to identify specific cell populations that could contribute to pathology.
Chapter 3 used laser capture microdissection to examine the glutamate signaling
pathway that is critical to brain function and that is thought to be disrupted in ASD. Data
from functional imaging and genetics studies support the theory that there is an
imbalance in the excitatory/inhibitory system of the brain of ASD patients (Pizzarelli &
Cherubini, 2011; Snijders, Milivojevic, & Kemner, 2013; Tebartz van Elst et al., 2014).
This study analyzed the expression of key glutamate receptor and transporter genes as
well as neurotrophic pathways in laser captured neurons and astrocytes from typically
developing and ASD brains. The results of this study further emphasize the need for
cell population based studies of brain pathology. The neuronal, but not glial, cell
population exhibited significant differences in the expression of several genes
comparing control and ASD brains. The expression of these genes was also
investigated in homogenate punched-dissected samples, which are gray matter
samples that are dissected using a 3.5 mm trephine punch and contained all gray
matter cell types. However, these changes were not found in homogenate punchdissected samples from the same subjects. This illustrates that the presence of multiple
cell populations in the experimental sample can present an inaccurate picture of brain
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pathology.
The gene and protein expression alterations discovered in the previously
discussed studies compelled our lab to ask how much could be learned about the
regulation of gene expression in a single cell population. With little to no data about the
potential molecular mechanism(s) underlying ASD brain pathology, we wanted to find
other gene or pathway alterations that could help us further understand the cell specific
data we produced. Chapter 4 discusses the development of a method to fully
characterize the transcriptional footprint of a specific cell type and what differences exist
comparing brains of control and ASD donors. This method was based on RNA-Seq,
which provides in-depth analysis of the transcriptome. This sequencing method
produces vast amounts of data including transcript copy number, differential expression
genes, rare isoforms, splicing variants, transcriptional start points, and identification of 5’
and 3’ ends of transcripts. Because the main objective was to determine feasibility of
this method, my research focused on identifying differentially expressed genes in single
populations of cells comparing ASD and typically developing control donors. My
research did not dismiss the other forms of data that RNA-Seq provides, but studies
investigating rare isoforms or alternative transcriptional regulators that are identified by
RNA-Seq are currently beyond the resources of our lab due to the small number of pairs
we currently have in our brain bank. We could be capable of performing this type of
analysis in the future through collaboration or addition of tissue to our bank. However,
these types of studies are beyond the scope of the current project.
Other methods could be used to examine differential expression, such as
microarrays and RT-qPCR. However, these methods only provide relative

28	
  

	
  
quantification of changes in transcription. RNA-Seq’s absolute quantification of
transcript through sequencing permits a more advance analysis than data collected
using microarrays. As our brain bank grows in number, absolute quantification allows
for the addition of pairs in separate analyses. Hence, over time we can analyze
additional pairs and add to our existing database. Also in future studies others can
retrospectively mine the database sequence information that is being created.
As more and more researchers adopt next generation sequencing techniques,
RNA-Seq is becoming a commonly used technique for transcriptional analysis, almost
replacing microarrays. However, herein we pushed the limits of this technology by
analyzing laser captured single cell populations. The nature of LCM samples makes
experimentation difficult because of the small amount of sample collected for analysis
and because of RNA degradation issues. Chapter 4 discusses the experimental
considerations and limitations of using LCM samples as well as advances in RNAbased methods that allows for low input sequencing.
The CDC reports that there has been a 78% increase in autism over the last
decade (Baio, 2014). Despite advances in the understanding of ASD, there is currently
no known cause. As presented in this dissertation, we examine ASD brain pathology at
the single cell level in order to identify molecular pathologies that could reveal targets
for the future development of treatments for ASD. In addition, LCM and RNA-Seq
technologies were paired to identify gene expression abnormalities in specific cell types,
a pairing that has not been successfully employed by other laboratories to date. ASD
research is thereby moved forward by developing methods to identify key molecular and
cellular pathways involved in the pathology of this disease.
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CHAPTER 2
ELEVATED GFAP PROTEIN IN ANTERIOR CINGULATE CORTICAL WHITE MATTER
IN MALES WITH AUTISM SPECTRUM DISORDER

INTRODUCTION
Autism spectrum disorder (ASD) is a developmental disorder characterized by
disruption of social interaction behaviors, reduced verbal and non-verbal
communication, and the presence of repetitive behaviors. The reported prevalence of
this disorder has grown rapidly with the current estimate of affected children to be 1 in
68 (Blumberg et al., 2013). A variety of factors including environmental exposures and
genetic abnormalities have been linked to ASD (Blake et al., 2013). Besides behavioral
deficits, ASD patients suffer from other comorbidities including seizures and
gastrointestinal abnormalities (Kral et al., 2013; Robinson, 2012). Current treatment
paradigms include drugs that offer individual symptomatic relief paired with behavioral
modification therapy. Reasonable treatment options are not available to significantly
improve quality of life, reverse the disorder, or arrest its progress. Thus, the need for
understanding the neuropathology of this disorder is crucial.
In addition to the behavioral deficits mentioned above, ASD patients display
anatomical brain abnormalities when compared to typically developing control subjects.
ASD brain pathology has been described using imaging methods such as fMRI and
brain volumetric analysis. Both developmental and structural changes have been found
in brain regions subserving behaviors that are affected in ASD. There is an aggressive
overgrowth in brain volume in ASD in both the cerebrum and cerebellum between ages
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two and four when compared to age-matched control subjects. By middle to late
childhood, ASD and age-matched control brains are similar in size (Courchesne et al.,
2011). White and gray matter in the brain do not undergo the same pathological
changes in size and development and it is unclear if gross brain abnormalities are linked
to specific cellular alterations and dysfunction (as reviewed by Amaral et al., 2008).
A consistent pathological finding in the ASD brain is abnormal white matter.
Diffusion tensor imaging (DTI) studies have been used to investigate white matter
pathology by measuring the amount of diffusion through brain matter. White matter is
more restrictive to the movement of water molecules than gray matter resulting in
decreased diffusion relative to gray matter. Increased diffusion of water in white matter
has been observed in ASD as compared to typically developing subjects, possibly
resulting from excess interstitial space in ASD (Groen et al., 2011). Several studies of
this nature have shown an overall increase in white matter size and a decrease in
structural integrity in ASD, further suggesting that cells within the white matter are
dysfunctional and/or structural changes exist in axons passing through white matter
(Groen et al., 2011; Ingalhalikar et al., 2011; Noriuchi et al., 2010; Radua et al., 2010;
Sundaram et al., 2008). The specific types of cells that contribute to these white matter
abnormalities in ASD are unknown. Macroglial cells, specifically astrocytes and
oligodendrocytes, are found abundantly in white matter tracts, whereas there are few
neuron cell bodies. Hence, it seems reasonable to speculate that dysfunction in
macroglia accounts for at least part of the ASD-associated deficits in white matter
integrity.
The purpose of this study was to examine the levels of two proteins expressed
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abundantly by brain astrocytes and oligodendrocytes in ASD. Glial fibrillary protein
(GFAP) is considered a marker of astrocytes. GFAP is up-regulated following an insult
or injury to the brain, additionally making it an indicator of CNS pathology (Sofroniew &
Vinters, 2010). Myelin oligodendrocyte glycoprotein (MOG) is marker protein for mature
myelin-producing oligodendrocytes. Since the myelin sheath has an integral role in
neurotransmission, myelin abnormalities could result in dysfunction of neuronal
conduction along axons in ASD. This study investigated GFAP and MOG protein
expression in white and gray matter from the ventral anterior cingulate cortex
(Brodmann area 24; BA24) and the anterior prefrontal cortex (BA10) using postmortem
brain tissues from age-matched typically developed control and ASD donors. These
brain areas were selected for their documented role in influencing behaviors
characteristically disrupted in ASD such as social interaction and repetitive behaviors.
Findings here show elevated GFAP immunoreactivity (ir) in ASD that is both matter and
brain area specific. The specificity of these findings guide future studies to elucidate the
cellular pathology associated with ASD.

Methods
Brain Tissues
Frozen tissue blocks containing BA24 and BA10 from 14 ASD donors and 14
typically developed control donors were obtained from Autism Tissue Program, Harvard
Brain Tissue Resource Center (Belmont, MA) and NICHD Brain and Tissue Bank for
Developmental Disorders (Baltimore, MD) (Table 2.1). This study was reviewed and
approved for exemption by the Institutional Review Board of East Tennessee State
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University under the Department of Health and Human Services exemption 45 CFR
46.101(b) relating to the use of publicly available unidentifiable pathology specimens.
ASD and control donors were matched prior to experimentation as closely as possible
by age primarily, but also by RNA quality (Table 2.1), to reduce the impact of these
factors on protein and mRNA data from the two groups. ASD donors met diagnostic
criteria outlined in the Diagnostic and Statistical Manual (DSM) IV for autistic disorder.
The Autism Diagnostic Interview-Revised (ADI-R) and other medical records were also
used to confirm diagnoses. Causes of death and comorbidities are not included in
Table 2.1 to protect the identities of the decedents. Cause of death for typically
developed control donors included asphyxia (3), drowning (3), motor vehicle accident
(2), heart attack (2), dilated cardiomyopathy (1), pneumonia (1), commotio cordis (1),
and an unknown cause (1). Cause of death for ASD donors included asphyxia (2),
heart attack (1), cardiac arrhythmia (1), congestive heart failure (1), cardiopulmonary
arrest (1), motor vehicle accident (1), acute respiratory distress syndrome (1), stopped
breathing (1), skull fracture (1), subdural he9morrhage (1), cancer (1), diabetic
ketoacidosis (1), and bowel obstruction (1).
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Table 2.1. Subject demographic information.
PMI
b
(hours)

Toxicology

Assays

7.8

21.33

No drugs reported

LCM , qPCR , WB

M

8

29.91

No drugs reported

LCM, qPCR, WB

BA24, BA10

17

M

7.5

30.75

Sertraline

LCM, qPCR, WB

BA24, BA10

5408

6

M

7

16

No drugs reported

LCM, qPCR, WB

BA24, BA10

5

4848

16

M

7.6

15

No drugs reported

LCM, qPCR, WB

BA24, BA10

6

5342

22

M

8.1

14

No drugs reported

LCM, qPCR, WB

BA24, BA10

7

5079

33

M

7.3

16

Ethanol

LCM, qPCR, WB

BA24, BA10

8

M3231M

37

M

7.4

24

No drugs reported

LCM, qPCR, WB

BA24, BA10

Pair

ID

Age

Gender

RIN

1

AN14757

24

M

2

AN07176

21

3

AN07444

4

a

Tissue

Controls
c

d

e

BA24, BA10

9

AN12137

31

M

7.3

32.92

No drugs reported

qPCR, WB

BA24, BA10

10

AN03217

19

M

7.6

18.58

No drugs reported

qPCR, WB

BA24, BA10

11

AN00544

17

M

7.8

28.92

No drugs reported

qPCR, WB

BA24, BA10

12

AN17425

16

M

7.5

26.16

No drugs reported

qPCR, WB

BA24, BA10

13

4590

20

M

7.6

19

No drugs reported

qPCR, WB

BA24, BA10

14

4670

4

M

7

17

No drugs reported

WB

BA10

7.54
0.09

22.11
1.75

18.51

No drugs reported

LCM, qPCR, WB

BA24, BA10

MEAN
SEM

20.21
2.46

ASD
1

AN04166

24

M

8.1

2

AN03935

20

M

8.6

28

No drugs reported

LCM, qPCR, WB

BA24, BA10

3

AN02987

15

M

6.5

30.83

No drugs reported

LCM, qPCR, WB

BA24, BA10

4

5144

7

M

8

3

No drugs reported

LCM, qPCR, WB

BA24, BA10

Risperidone,
Fluvoxamine, Clonidine,
Insulin

LCM, qPCR, WB

BA24, BA10

5

5302

16

M

6.6

20

6

5176

22

M

7.1

18

Risperidone

LCM, qPCR, WB

BA24, BA10

LCM, qPCR, WB

BA24, BA10

7

5297

33

M

7.1

50

Quetiapine, Fluoxetine,
Valproate, Ziprasidone

8

5027

37

M

7.7

26

Risperidone, Fluvoxamine

LCM, qPCR, WB

BA24, BA10

qPCR, WB

BA24, BA10

9

AN11989

30

M

7.7

16.06

Sertraline, Clomipramine,
others for pain
f
management and CHF

10

AN07817

19

M

7.2

14.83

No drugs reported

qPCR, WB

BA24, BA10

11

AN00764

20

M

8

23.66

Minocycline

qPCR, WB

BA24, BA10

12

AN04682

15

M

7.6

23.23

No drugs reported

qPCR, WB

BA24, BA10

13

4999

20

M

7

14

No drugs reported

qPCR, WB

BA24, BA10

14

5308

4

M

6.5

21

No drugs reported

WB

BA10

MEAN
20.14
7.41
21.94
SEM
2.42
0.17
2.84
g
P value
0.98
0.51
0.96
a
RNA integrity number (index of RNA quality)
b
Postmortem interval
c
Laser capture microdissection
d
Quantitative polymerase chain reaction
e
Western blotting
f
Congestive heart failure
g
Results of an independent t-test comparing control and ASD groups.
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Tissue Preparation and Sectioning
Frozen tissue sections (50 µm) of BA24 and BA10 were cut using a cryostat
microtome (Leica CM3050S) and tissue samples were punch-dissected from sections
using a disposable 3.5 mm trephine. White and gray matter samples were separately
collected for each brain area (Fig 2.1A). Frozen tissue sections (10 µm) cut using the
same microtome were prepared as previously described for laser capture
microdissection (LCM) (Ordway, Szebeni, Duffourc, Dessus-Babus, & Szebeni, 2009).
Western Blotting
Protein from punch-dissected samples was isolated using ice-cold Tris-EDTA
buffer with a protease inhibitor cocktail (Thermo Scientific, Rockford, IL) and sonication
for 20 sec. Equal amounts of protein (10 µg per lane; Micro BCA Protein Assay Kit;
Thermo Scientific, Rockford, IL) per sample were diluted 1:1 in SDS sample buffer and
separated by electrophoresis using pre-cast Tris-Glycine gels (NuSep, Bogart, GA).
Subsequently, resolved proteins were transferred onto nitrocellulose membranes.
Membranes were incubated with 5% milk-based blocking agent (Bio-Rad, Hercules,
CA), and then incubated with primary antibody overnight at 4o C. Primary antibodies
included GFAP (1:500, Sigma-Aldrich, St. Louis, MO), MOG (1:1500, Abcam,
Cambridge, MA), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; control for
loading; 1:1000, EMD Millipore, Billerica, MA). Membranes were washed with TBSTween (0.5%) buffer (Boston BioProducts, Ashland, MA) three times for 10 min,
incubated with anti-mouse (1:5000) and anti-rabbit (1:20,000) secondary antibody for
one h at 22o C and washed again three times for 10 min with TBS-Tween (0.5%) buffer
(Boston BioProducts, Ashland, MA). Immunochemically identified bands were detected
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using horseradish peroxidase conjugated secondary antibodies reacted with the
chemiluminescent substrate, Amersham ECL Prime Western Blotting Detection
Reagent (GE Healthcare, Piscataway, NJ). Bands were visualized and analyzed using
a G:Box imager (Syngene, Frederick, MD). Paired ASD and typically developed control
samples were run on the same gel in triplicate along with a set of protein standards.
Data were normalized to GAPDH-ir measured on the same blot, after stripping GFAP
and MOG antibodies. Band densities were measured using GeneTool software
(Syngene, Frederick, MD).
Laser Capture Microdissection
Laser capture of astrocytes identified using a rapid immunohistochemical stain
for GFAP (Fig. 2.1B-D) was performed on an Arcturus XT (Life Technologies, Grand
Island, NY) as previously described (Ordway et al. 2009).
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Figure 2.1. Tissue collection of white and gray matter and laser capture
microdissection of astrocytes. Panel A shows gray and white matter regions in BA24
identified with GFAP immunostaining (2x magnification). Panel B shows GFAP
immunostained cells (individuals cell indicated by arrows) in white matter (40x
magnification). Shown in panel C is the absence of laser captured cells in the tissue
section following capture (20x magnification). Panel D shows the GFAP
immunoreactive cells adhered to the polymer cap (20x magnification).
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Quantitative Polymerase Chain Reactions
Total RNA was isolated from tissue samples using the Maxwell simplyRNA LEV
kit (Promega, Madison, WI). The quality of RNA extracted from brain tissue samples
was assessed using the Bioanalyzer RNA 6000 Nano chip (Agilent Technologies, Santa
Carla, CA) and all samples had RNA integrity number (RIN) values of ≥ 6.5. RNA was
converted to double-stranded cDNA using Superscript III reverse transcriptase kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Quantitative realtime PCR (qPCR) was performed using cDNA template, 2x Platinum PCR quantitative
supermix-UDG (Invitrogen, Grand Island, NY), 10 µM fluorogenic probe, and 250 nM
gene specific primers on the Stratagene MX3000P (Agilent Technologies, Santa Carla,
CA). Intron-spanning primers were designed using PrimerQuest software (Integrated
DNA Technologies, Coralville, IA) in a region of the target gene containing no
secondary structure as determined by mFold3 (Zuker, 2003) shown in Appendix B. For
some genes, primers were obtained from Qiagen (Valencia, CA). Each sample was
analyzed in triplicate. A five point standard curve on each plate was used to determine
reaction efficiency and copy number of amplicons. Gene expression data were
normalized to the geometric mean of three housekeeping genes, GAPDH, TBP, and
Ribo18S1. Fold-differences in gene expression between control and ASD groups were
determined using the 2-ΔΔCT method (Livak & Schmittgen, 2001). To quantify RNA
levels from laser captured astrocytes, a semi-quantitative end-point PCR method was
used as described previously (Ordway et al., 2009), wherein target genes were
normalized with the average of two reference genes, GAPDH and Ribo18S1.
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Statistical Analysis
A Grubb’s test was used or remove outliers in data sets (Grubbs, 1950). Data
from ASD and typically developed control donors were statistically compared using the
Student’s t-test for independent measures. As an additional check (see Results), data
were also analyzed using the t-test for paired measures and the statistical findings for
these paired tests are included in supplementary materials. Differences were
considered statistically significant at p < 0.05. Pearson’s correlation analysis was used
to determine possible effects of age, RIN, and postmortem interval (PMI) on dependent
variables. Because many correlations were examined, a p < 0.01 was chosen a priori to
reduce the risk of type I errors. Statistical analysis was performed using SPSS (version
21, IBM, New York, NY) and graphed using Prism (version 5.0b, GraphPad Software,
La Jolla, CA).

RESULTS
Donors and tissues.
Careful pairing of ASD and typically developed control donors was performed
prior to the initiation of experiments as described in the Methods. As a result, there
were no statistically significant differences between the two groups of donors when
comparing ages, RINs or PMIs (Table 2.1).
Western blot analysis of white and gray matter GFAP and MOG
Levels of GFAP-ir and MOG-ir were measured in four brain regions, including
white and gray matter areas of both BA10 and BA24. Except for BA10 gray matter
(r2=0.68; p=0.001) from ASD donors only, there were not significant correlations
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between age and levels of GFAP-ir or MOG-ir in any of the brain regions (Table 2.2).
This lack of correlation was observed whether examining potential age effects in control
and ASD separately, or when examining age versus protein levels for all subjects from
both groups. Likewise, levels of GFAP-ir and MOG-ir did not significantly correlate with
either RIN or PMI in any brain region (Table 2.2).
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Table 2.2. Pearson’s correlation analysis of GFAP-ir and MOG-ir for BA24 and BA10
white (WM) and gray (GM) matter versus age, RIN, and PMI.
All Subjects

BA10

BA24

Age

WM GFAP
WM MOG
GM GFAP
GM MOG
WM GFAP
WM MOG
GM GFAP
GM MOG

RIN

PMI

r2

p value

r2

p value

r2

p value

0.03
0.00
0.06
0.00
0.03
0.05
0.20
0.20

0.45
0.81
0.25
0.89
0.03
0.40
0.03
0.03

0.00
0.04
0.01
0.00
0.03
0.00
0.00
0.02

0.97
0.34
0.70
0.93
0.54
0.89
0.92
0.49

0.04
0.08
0.08
0.00
0.01
0.00
0.07
0.10

0.35
0.19
0.18
0.93
0.71
0.98
0.25
0.15

Control Subjects Only

BA10

BA24

Age

WM GFAP
WM MOG
GM GFAP
GM MOG
WM GFAP
WM MOG
GM GFAP
GM MOG

RIN

PMI

r2

p value

r2

p value

r2

p value

0.15
0.05
0.04
0.14
0.46
0.28
0.18
0.03

0.24
0.48
0.52
0.23
0.07
0.18
0.19
0.62

0.02
0.13
0.31
0.01
0.10
0.05
0.07
0.04

0.65
0.25
0.05
0.81
0.44
0.58
0.42
0.53

0.03
0.17
0.13
0.08
0.01
0.00
0.03
0.08

0.57
0.18
0.22
0.38
0.82
0.91
0.61
0.40

ASD Subjects Only

BA10

BA24

Age

WM GFAP
WM MOG
GM GFAP
GM MOG
WM GFAP
WM MOG
GM GFAP
GM MOG

RIN

PMI

r2

p value

r2

p value

r2

p value

0.02
0.02
0.17
0.04
0.32
0.08
0.68
0.06

0.68
0.69
0.19
0.53
0.15
0.51
0.001
0.46

0.01
0.02
0.02
0.01
0.33
0.00
0.00
0.01

0.75
0.66
0.65
0.78
0.14
0.87
0.94
0.82

0.08
0.05
0.06
0.00
0.08
0.02
0.38
0.21

0.38
0.53
0.45
0.87
0.49
0.71
0.04
0.16
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Age was the primary criteria for matching control and ASD donors. Given the
lack of consistent effects of age on GFAP-ir levels, further statistical analyses of
Western blot data utilized a t-test for independent measures. Significantly elevated
levels of GFAP-ir were observed in BA24 white matter of ASD donors as compared to
control donors (Fig. 2.2A; p=0.008). In contrast, MOG-ir levels were similar in these
same tissues from control and ASD donors (Fig. 2.2A; p=0.85). Furthermore, no
significant differences were observed for GFAP-ir or MOG-ir levels comparing control
and ASD donors for BA24 gray matter (Fig. 2.2B; GFAP p=0.88; MOG p=0.67), BA10
white matter (Fig. 2.2C; GFAP p=0.13; MOG p=0.17), or BA10 gray matter (Fig. 2.2D;
GFAP p=0.50; MOG p=0.94). Since the study was originally set up and performed in a
matched pair design (see Methods), we also examined the data using a paired t-test,
which yielded very similar results (Table 2.3).
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Figure 2.2. Western blot analysis of GFAP-ir and MOG-ir in punch-dissected white and
gray matter from BA24 and BA10 of typically developing control donors (open symbols)
and ASD donors (closed symbols). Immunoreactivity levels are normalized to GAPDHir determined on the same blot. (A) BA24 white matter; (B) BA24 gray matter; (C) BA10
white matter; (D) BA10 gray matter. Statistical significance is noted in the horizontal bar
above the data points.

Table 2.3. Paired Student’s t-test analysis of GFAP-ir and MOG-ir for BA24 and BA10
white and gray matter.
BA24

BA10

WM

GM

WM

GM

GFAP

p=0.006

p=0.85

p=0.10

p=0.39

MOG

p=0.64

p=0.54

p=0.21

p=0.87
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qPCR analysis of GFAP and MOG expression
Because ASD was associated with elevated GFAP protein levels in BA24, we
examined gene expression levels of glial markers using RNA isolated from
homogenates of white or gray matter from ASD and control donors. There were no
significant correlations between age or PMI with levels of GFAP or MOG gene
expression. RIN significantly correlated with levels of GFAP expression (p=0.003) only
in BA24 white matter and only in control subjects (Table 2.4). No significant differences
in the levels of expression of either GFAP (Fig. 2.3A; p=0.61) or MOG (Fig 2.3A;
p=0.20) were observed comparing control and ASD donors. Comparison of gene
expression levels in BA24 white matter of control and ASD donors using a paired t-test
yielded similar results (Table 2.5). Likewise, gene expression for GFAP and MOG in
gray matter was not different comparing control and ASD donors as assessed using an
independent (Fig. 2.3B; GFAP, p=0.52; MOG, p=0.95) or a paired t-test (Table 2.5).
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Table 2.4. Pearson’s correlations analysis of GFAP and MOG expression for BA24
white (WM) and gray (GM) matter and BA24 white and gray matter laser captured
astrocytes versus age, RIN, and PMI.
All Subjects
Age

GM

WM

2

GFAP
MOG
LCM GFAP
GFAP
MOG
LCM GFAP

r
0.00
0.12
0.13
0.00
0.00
0.07

p value
0.79
0.10
0.21
0.78
0.77
0.32

RIN
2

r
0.01
0.06
0.43
0.04
0.01
0.12

p value
0.72
0.22
0.01
0.41
0.73
0.19

PMI
2

r
0.01
0.02
0.02
0.02
0.18
0.25

p value
0.58
0.56
0.64
0.55
0.048
0.051

Control Subjects Only
Age

GM

WM

2

GFAP
MOG
LCM GFAP
GFAP
MOG
LCM GFAP

r
0.00
0.27
0.25
0.00
0.06
0.28

p value
0.99
0.07
0.25
0.94
0.45
0.18

RIN
2

r
0.56
0.03
0.34
0.21
0.00
0.10

p value
0.003
0.55
0.17
0.18
0.85
0.45

PMI
2

r
0.00
0.00
0.15
0.07
0.01
0.25

p value
0.98
1.00
0.39
0.46
0.79
0.21

ASD Subjects Only
Age

GM

WM

2

GFAP
MOG
LCM GFAP
GFAP
MOG
LCM GFAP

r
0.02
0.01
0.06
0.01
0.01
0.01

p value
0.62
0.74
0.59
0.73
0.73
0.82

RIN
2

r
0.15
0.13
0.50
0.15
0.01
0.26
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p value
0.19
0.25
0.08
0.24
0.79
0.19

PMI
2

r
0.05
0.07
0.50
0.01
0.48
0.26

p value
0.45
0.40
0.08
0.76
0.02
0.19

	
  

Figure 2.3. Levels of expression of
GFAP and MOG in punch-dissected white
(A) and gray (B) matter from BA24 of
typically developing control donors (open
symbols) and ASD donors (closed
symbols). Gene expression levels are
normalized to the geometric mean of
stable references genes (GAPDH, TBP,
and Ribo18S1). No statistically
significant differences were observed.

Table 2.5. Paired Student’s t-test analysis of GFAP and MOG expression for BA24
white and gray matter and BA24 white and gray matter laser captured astrocytes.
BA24
GFAP
MOG

WM Punch
p=0.67
p=0.18

GM Punch
p=0.58
p=0.96

WM LCM
p=0.82

GM LCM
p=0.15

	
  
	
  
Laser-captured BA24 astrocyte PCR analysis for GFAP expression 	
  
We considered the possibility that the use of LCM to specifically capture GFAPimmunoreactive astrocytes for PCR analysis of GFAP gene expression might yield a
more accurate analysis of astrocyte GFAP gene expression levels than measuring gene
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expression in mRNA isolated from homogenates of cortical tissue. Hence, LCM
collected GFAP-immunoreactive astrocytes from both BA24 gray and white matter from
eight of the control-ASD donor pairs used for protein studies above. There were no
significant correlations between age or PMI with levels of GFAP or MOG gene
expression. RIN significantly correlated with levels of GFAP expression (p=0.01) only in
BA24 white matter and only when all subjects from both groups were combined (Table
2.4). Levels of GFAP expression were not different comparing control and ASD donors,
in both white (p=0.93;) and gray matter (p=0.11) cell populations analyzed using
independent t-test (Fig. 2.4) or a paired t-test (Table 2.5).

Figure 2.4. Levels of expression of GFAP in laser captured astrocytes from BA24 white
and gray matter of typically developing control donors (open symbols) and ASD donors
(closed symbols). Gene expression levels are normalized to the average of levels of
expression of references genes (GAPDH and Ribo18S1).
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DISCUSSION
Autism has been considered a disorder of aberrant connections between and
within brain regions. This theory of disrupted connectivity is supported by findings of
reduced axon thickness and neuronal disorganization (Courchesne et al., 2007;
Minshew & Williams, 2007; Zikopoulos & Barbas, 2010). Most ASD research to date
has focused on pathology of neurons with little regard to the other major cell types of
the brain. Physiologically, glia assist neurons in a variety of ways including protecting
neurons from cytotoxic glutamate exposure, providing vital growth factors essential for
neuronal survival, and providing support for electrical conduction along axons.
Pathology of glia could lead to the aberrant functioning of neurons and could account for
imaging abnormalities seen in ASD white matter (Zeidán-Chuliá et al., 2014), making it
imperative to determine the possible contributory role of glial to the etiology of this
disease.
Within the ASD field, protein expression studies utilizing postmortem brain
tissues have been mostly limited to the examination of brain areas, as whole entities,
with little regard for differences between white and gray matter. Glial cells occur in both
gray and white matter. However, the function and types of glia differ between these
types of brain tissue. For example, protoplasmic astrocytes are found in gray matter,
whereas fibrous astrocytes are present in white matter. Each of these astrocytes types
have their own function and structure (Kimelberg, 2010). Increases in GFAP-ir have
been observed in the frontal and parietal cortices, cerebellum, and the anterior cingulate
gyrus of autistic subjects when compared to age-matched controls, suggesting the
presence of reactive astrogliosis (Laurence et al., 2005; Vargas et al., 2005). These
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studies used homogenized brain tissues without anatomically distinguishing between
white and gray matter or cell types within these brain regions. The present study is the
first to evaluate two glial cell markers separately in gray and white matter. The results
of this study demonstrate elevated levels of the astrocyte marker, GFAP, specifically in
white matter in BA24 of the ventral anterior cingulate cortex from ASD donors as
compared to matched typically developing control donors.
Astrocytes compose the bulk of activated glial cells in ASD, although microglia
are also activated (Vargas et al., 2005). Viral and inflammatory processes as well as
direct brain trauma can increase astrocyte reactivity (Sofroniew & Vinters, 2010). Many
cytokines and inflammatory factors are up-regulated in the ASD brain (Pardo, Vargas, &
Zimmerman, 2005), factors that may mediate glial activation and subsequent increases
in GFAP expression in ASD. Glia activation is a phasic process that involves many
different biochemical pathways. Based on the type of insult, astrocytes can return to a
non-reactive state, trigger cellular mechanisms of defense, and/or induce astrocytic
proliferation aimed at remodeling the affected brain area (Pekny, Wilhelmsson, &
Pekna, 2014). The phasic nature of GFAP regulation might explain the large range of
GFAP-ir levels observed in white and gray matter of all subjects in the present study.
GFAP expression in BA24 white matter was similar comparing ASD and control
donors, despite a difference in GFAP protein levels. Others have noted a different
response pattern in translational and transcriptional regulation of GFAP as well as a
biphasic expression of GFAP in activated cells (Tawfik, LaCroix-Fralish, NutileMcMenemy, & DeLeo, 2005) which could account for the apparent discrepancy in the
present study. We also considered that homogenate tissue samples contain a variety of
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cells that could make it difficult to distinguish the cellular source of pathology.
Therefore, potential gene expression differences were also interrogated in laser
captured astrocytes. However, no change in the gene expression of glial markers was
found in laser captured astrocyte populations from control and ASD brains. It is also
possible that GFAP protein increases are occurring in other glial cell types that also
express GFAP, such as microglia, which were not studied here. Neurons and other glial
cell types can release diffusible factors during cellular stress that can cause cellular
activation to occur (Sofroniew & Vinters, 2010). Future studies are needed to determine
the specific mechanism and cellular source of white matter GFAP activation in ASD.
Previous research has implicated a role of oligodendrocyte pathology in ASD.
Increases in myelin density around the corpus callosum in the ASD brain has been
demonstrated using magnetization transfer imaging (MTI), a method used to visualize
myelin in the brain (Gozzi et al., 2012). The myelin increase may result from aberrant
signaling by growth factors that mediate myelination in the white matter (Zaccaria,
Lagace, Eisch, & McCasland, 2010; Zikopoulos & Barbas, 2013). Oligodendrocytes are
also very sensitive to metabolic changes that can be produced by various pathologies
(Butts, Houde, & Mehmet, 2008). Oxidative stress and pro-inflammatory events in ASD
could also contribute to pathology in this cell type (Angelidou et al., 2012; Ghanizadeh
et al., 2012). In the present study, no differences in MOG protein levels or gene
expression were observed comparing control and ASD donors. Since MOG is
expressed in mature myelinating oligodendrocytes, it remains possible that
oligodendrocytes at earlier stages of differentiation may be selectively or preferentially
affected in ASD due to the above-mentioned evidence of aberrant signaling during the
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cell maturation process. Further study measuring proteins that are specifically
expressed by immature oligodendrocytes is warranted.
We found that elevated GFAP protein levels in ASD were not only specific to
white matter relative to gray matter, but also occurred in BA24 but not in BA10. Among
many attributes of BA24, it mediates behaviors related to social interaction (Gariépy et
al., 2014), deficits of which are hallmark behavioral traits of ASD. Numerous previous
studies have demonstrated pathology in BA24. Imaging and immunohistochemical
studies have shown significant differences in BA24 between ASD and control brains
including early developmental brain overgrowth in ASD (Minshew & Williams, 2007) as
well as prominent glial activation in ASD (Vargas et al., 2005). BA24 also receives
direct inputs from the limbic system, an area of the brain that modulates social and
emotional behaviors and that also displays prominent ASD pathology (Devinsky,
Morrell, & Vogt, 1995).
Limitations
While white and gray matter were dissected and analyzed separately, these
samples still included a variety of cell types found within each type of tissue. The
availability of postmortem tissue itself is a severe limitation in current and previous ASD
studies. Available brain specimens are not only few in number, but also those available
are from donors who were exposed to a number of medications that could influence
experimental outcomes. In selecting and pairing study subjects, we used exclusion
criteria to narrow down the study population to reduce variation in experimental data.
Subjects with any co-morbidity, including epilepsy, were excluded. One ASD subject
did have a seizure prior to death but had no reported history of seizure disorders.
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Because of the selection criteria of this study, it is important to note that our data
reflects pathology in a specific subset (no seizure disorders) of the ASD population.

CONCLUSION AND FUTURE DIRECTION
This is the first study that demonstrates distinct protein expression abnormalities
in white matter not gray matter from BA24 brain tissue in humans. This finding
suggests a very distinct cellular response to pathology in this brain region that did not
extend to the other cortical region in this study. While this study is important in moving
the field toward the identification of a pathological target, it lacks the clarity and depth
needed to identify a distinct cellular source or pathophysiological mechanism. ASD
patients symptomatically present with vast differences in abnormal behaviors. Using an
approach targeted at molecular pathology within a single cell population, a common
cellular dysfunction may be found that could unify our conceptualization of ASD brain
pathology throughout the spectrum. In addition, identification of key cellular
abnormalities could result in the development of novel targeted treatments for ASD.
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CHAPTER 3
NTRK2 EXPRESSION DEFICIT IN LASER CAPTURED PYRAMIDAL
NEURONS FROM THE ANTERIOR CINGULATE CORTEX IN MALES WITH AUTISM
SPECTRUM DISORDER

Background
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that includes
repetitive behaviors and impairments in social communication and interaction (American
Psychological Association, 2013). In recent years, ASD and disorders with associated
autism behaviors have largely been attributed to genetic etiology in the literature (as
reviewed by Jeste & Geschwind, 2014). However, it is likely that the heterogeneity of
ASD results from a complex interplay of inherited genetics and developmental
influences that result in abnormal intercellular communication in the brain. It is
anticipated that areas of the brain that modulate the behaviors that are disrupted in ASD
are particularly vulnerable to the cellular pathobiology of ASD likely includes disrupted
connectivity between discrete areas of the brain that modulate behaviors that are
abnormal from infancy.
The anterior cingulate cortex (ACC), an area of the brain that is involved in social
and repetitive behaviors (Amaral et al., 2008), has consistently displayed abnormalities
in ASD as revealed through imaging and neuroanatomical studies. Functional MRI was
used to demonstrate hypoactivation of the anterior cingulate cortical activity between
subjects with ASD and unaffected control subjects when conducting social tasks (as
reviewed by Di Martino et al., 2009). However, resting-state differences have also been

53	
  

	
  
identified in the ACC, suggesting that this brain area may display inherent alterations
that are task-independent, but may substantially augment functional connectivity
disassociations (Kennedy & Courchesne, 2008). Alternative methods including SPECT
(Sasaki et al., 2010), EEG (Santesso et al., 2010; Sokhadze et al., 2010; Vlamings,
Jonkman, Hoeksma, van Engeland, & Kemner, 2008), PET (Buchsbaum et al., 2001;
Hall, Szechtman, & Nahmias, 2003; Nakamura et al., 2010), and fractional anisotropy
(Thakkar et al., 2008) have also demonstrated abnormalities in the cingulate cortex in
ASD.
The few postmortem studies that have focused on the anterior cingulate cortex
have identified molecular and anatomical differences between ASD and
developmentally normal control brain tissue. Stereology studies using the neocortex of
the anterior cingulate indicated that neurons were smaller and demonstrated increased
cell packing density (Simms, Kemper, Timbie, Bauman, & Blatt, 2009). Reductions in
both mRNA and protein levels of the axonal guidance proteins plexinA4 and roundabout
2 were identified in tissue homogenates of ACC from ASD donors (Suda et al., 2011),
as well as alterations in serotonin (Thanseem et al., 2010) and GABA (Oblak, Gibbs, &
Blatt, 2009, 2010) related genes. Interestingly, increased gene expression in the
transcriptional control factor, Sp1, was found in postmortem ACC from ASD donors,
which could have wide spread implications and contribute to the complexity of ASD.
Collectively, these studies demonstrate that pathology in the ACC exists in autism.
However, little is known about what types of cells in the ACC are affected.
Pyramidal neurons in layer III of the neocortex are key cellular mediators of
neural output of the anterior cingulate cortex. These pyramidal cells are excitatory
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glutamatergic neurons that have a complex synaptic relationship with many other cell
types in other neocortical layers of the ACC, including inhibitory neurons, glia, and longrange projecting glutamate neurons of layer 5. The current study was undertaken to
investigate specific cellular pathology of pyramidal cells in layer III of the ACC from ASD
donors. The levels of expression of several glutamate-related genes were measured
specifically in pyramidal neurons captured by laser microdissection from layer III of the
ACC from postmortem brain tissue from ASD donor and developmentally normal control
subject brain tissue. The glutamate-related genes chosen for study were those
associated with ASD identified in gene association, laboratory animal, and/or
postmortem pathology studies (Barnby et al., 2005; Dölen et al., 2007; Jamain et al.,
2002; Pinto et al., 2010; Purcell, Jeon, Zimmerman, Blue, & Pevsner, 2001; Rainey &
van der Walt, 1998) and/or because of their strong association with glutamatergic
neurotransmission. Additionally, two neurotrophic factor genes (BDNF and NTRK2)
were studied because of the link between glutamatergic transmission and BDNF
signaling (Browne & Lucki, 2013) and the association of BDNF and NTRK2 pathology in
ASD (Correia et al., 2010). The findings of this study demonstrate that ACC in ASD is
associated with abnormal levels of expression of several genes related to glutamate
neurotransmission, with the most striking finding being a robust reduction of NTRK2
gene expression.

Methods
Brain Tissue
Brain tissues for ASD and control donors were provided by the National Institutes
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for Child Health and Development (NICHD) Brain and Tissue Bank (Baltimore, MD) and
the Autism Tissue Program (Belmont, MA). In total, brain tissue from 12
developmentally normal control donors and 12 ASD donors were used for the different
experiments (see Table 3.1). Comorbidities and causes of death were not included in
the table in order to protect donor identities. However, control donors died by drowning
(3 donors), heart condition (3 donors), trauma (3 donors), asphyxia (1 subject),
pneumonia (1 subject), and unknown cause (1 subject). It should be mentioned that
one control subject was diagnosed with depressive disorders and died by suicide. The
ASD donors died by trauma (3 donors), asphyxia (3 donors), acute respiratory distress
syndrome (1 subject), cardiopulmonary arrest (1 subject), cancer (1 subject),
ketoacidosis (1 subject), bowel obstruction (1 subject), and cardiac arrhythmia (1
subject). The ASD group had one subject that the ASD diagnosis could not be
medically confirmed after death and one subject that had a single seizure episode but
did not have a medical diagnosis of seizure disorder. The samples were closely
matched by gender and age. Additionally, we analyzed RNA integrity values (RIN,
index of RNA quality) in matched pairs of donors prior to experimentation to be sure
these were closely matched for the paired analyses (Auer et al., 2003).
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Table 3.1. Subject demographic information.
Pair

ID

PMI
b
(hours)

Toxicology

Assays

7.8

21.33

No drugs reported

LCM , qPCR

Age

Gender

RIN

a

Tissue

Control Donors
c

d

1

AN14757

24

M

BA24, BA10

2

AN07176

21

M

8

29.91

No drugs reported

LCM, qPCR

3

AN07444

17

M

7.5

30.75

Sertraline

LCM, qPCR

BA24

4

5408

6

M

7

16

No drugs reported

LCM, qPCR

BA24, BA10

5

4848

16

M

7.6

15

No drugs reported

LCM, qPCR

BA24, BA10

6

5342

22

M

8.1

14

No drugs reported

LCM, qPCR

BA24, BA10

7

5079

33

M

7.3

16

Ethanol

LCM, qPCR

BA24, BA10

8

M3231M

37

M

7.4

24

No drugs reported

LCM, qPCR

BA24, BA10

9

4590

20

M

7.6

19

No drugs reported

LCM, qPCR

BA10

BA24, BA10

Mean ± SEM
(BA24 donors)

22.0
±3.4

7.59
±0.13

20.9
±2.4

Mean ± SEM
(BA10 donors)

22.4
±3.4

7.60
±0.13

19.4
±1.9

18.51

No drugs reported

LCM, qPCR

BA24, BA10
BA24, BA10

ASD Donors
1

AN04166

24

M

8.1

2

AN03935

20

M

8.6

28

No drugs reported

LCM, qPCR

3

AN02987

15

M

6.5

30.83

No drugs reported

LCM, qPCR

BA24

4

5144

7

M

8.0

3

LCM, qPCR

BA24, BA10

5

5302

16

M

6.6

20

LCM, qPCR

BA24, BA10

6

5176

22

M

7.1

18

LCM, qPCR

BA24, BA10

7

5297

33

M

7.1

50

LCM, qPCR

BA24, BA10

8

5027

37

M

7.7

26

LCM, qPCR

BA24, BA10

9

4999

20

M

7.0

14

No drugs reported
Risperidone,
Fluvoxamine,
Clonidine, Insulin
Risperidone
Quetiapine,
Fluoxetine,
Valproate,
Ziprasidone
Risperidone,
Fluvoxamine
No drugs reported

LCM, qPCR

BA10

Mean ± SEM
(BA24 donors)

21.6
±3.4

7.46
±0.27

24.3
±4.8

Mean ± SEM
(BA10 donors)

22.2
±3.3

7.53
±0.24

23.4
±5.4

0.94

0.68

0.53

g

P value (BA 24)
g

P value (BA10)
0.98
0.79
0.60
RNA integrity number (index of RNA quality)
b
Postmortem interval
c
Endpoint PCR analysis of reversed transcribed RNA isolated from cells collected by laser capture microdissection
d
Quantitative polymerase chain reaction of reverse transcribed RNA isolated from punch-dissected tissues
g
Results of a two-tailed independent t-test comparing control and ASD groups.
a
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Tissue preparation
Blocks of tissue containing ACC, specifically Brodmann area 24 (BA24), and
prefrontal cortex Brodmann area 10 (BA10) were received and stored at -80oC. All
brain tissues were obtained from the left hemispheric side except AN03935. Tissue
homogenates used for quantitative PCR were obtained using a 3 mm trephine to punchdissect a 50 µm section of gray matter from the anterior cingulate that contained all 6
neocortical layers. A cryostat microtome was used to section tissue blocks for laser
capture microdissection (LCM). Tissue from the cortex was sectioned at -20oC and 10
µm sections were mounted slides that were immediately placed in a chilled microslide
on ice. Between each tissue block, all physical elements of cryosectioning were
thoroughly cleaned with 100% ethanol to avoid any cross contamination. Sectioned
tissue was desiccated at room temperature for 5 minutes and stored at -80oC until use.
All subject tissue pairs were sectioned or punch-dissected on the same day to ensure
storage time is identical for all tissue pairs.

Laser capture microdissection
Neurons were visualized by staining frozen 10 µm thick sections with the
Histogene staining kit (Life Technologies; Grand Island, NY) according to
manufacturer’s instructions. In short, the protocol used a cresyl violet stain on an
ethanol fixed slide followed by a series of dehydration steps. Stained slides were
placed in a vacuum chamber until ready for LCM. Astrocytes were identified using a
modified glial fibrillary acidic protein (GFAP) rapid immunohistochemistry protocol as
previously described (Chandley et al., 2012; Ordway et al., 2009). Briefly, 10 µm slides
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were fixed in acetone (5 min), blocked in horse serum (10 min), incubated with GFAP
antibody (10 min; ThermoFisher, Pittsburgh, PA) anti-mouse antibody (5 min;
Vectastain, Burlingame, CA), and avidin-biotinylated horseradish peroxidase (5 min;
Jackson ImmunoResearch, West Grove, PA). The GFAP stain was visualized using
diaminobenzidine (Sigma; St. Louis, MO) with ammonium nickel sulfate (Sigma; St.
Louis, MO) for 5 min, then for an additional 5 min with 0.1% H2O2. Afterwards, the slide
was ethanol dehydrated with 5 min incubation in xylene. The slide is kept in a vacuum
chamber for 10 min prior to LCM.
LCM was performed using an Arcturus XT (Life Technologies) instrument.
Neurons were extracted onto CapSure macrocaps using a 25 µm spot size that is first
cut by a ultraviolet (UV) laser and then placed onto the cap by infrared (IR) laser
spotting. Neurons were morphologically identified in layer III of the neocortex at 40X
magnification (Figure 3.1C-D). Astrocytes were captured using an Arcturus Veritas (Life
Technologies; Grand Island, NY) instrument. Astrocytes were morphologically identified
at 60X magnification and placed onto caps by IR laser only using a 10 µm spot size
(Figure 3.1E-F). Cells were removed from cap using lysis buffer incubation at 42oC.

59	
  

	
  

Figure 3.1. Laser capture microdissection of pyramidal neurons and astrocytes.
Shown in Panel A is the absence of laser captured nissl-stained pyramidal
neurons from cortical layer 3 in BA24 gray matter tissue following capture (20x
magnification). Panel B shows those cells adhered to the polymer cap (20x
magnification). Panel C and D illustrate the before (C) and after (D) capture images for
nissl-stained BA24 pyramidal neurons (40x magnification). Panel E and F shows the
same laser capture process for GFAP immunostained astrocytes in BA24 gray matter
(60x magnification).

RNA preparation and reverse transcriptase
Total RNA was extracted from tissue homogenates using the Maxwell
simplyRNA LEV kit (Promega, Madison, WI). Laser captured cells using the
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RNAqueous Micro kit with DNase treatment (Life Technologies; Grand Island, NY).
RNA quality was assessed by measuring RIN values obtained using the Agilent 2100
Bioanalyzer (Agilent Technologies; Santa Clara, CA). RNA samples were reverse
transcribed into cDNA using the Superscript III kit (Life Technologies; Grand Island, NY)
that contained oligodT and random hexamer primers.

Quantitative polymerase chain reaction
Gene specific primers were either designed using Mfold web server software
(Zuker, 2003) and primer quest design software (IDT; Coralville, IA) to generate 100
base-pair amplicons to span exon junctions. Some primers were purchased from a
vendor (Qiagen; Valencia, CA). Gene primer sequences are shown in Appendix B. To
quantify transcripts, endpoint PCR was used for RNA isolated from laser captured cells
and real-time quantitative PCR (qPCR) was used for RNA isolated from tissue
homogenates as previously described (Ordway et al., 2009; Xiang et al., 2008). For
PCR reactions (BDNF, GRIN2D, GRIN2B, and GRM8) that were initially problematic
using 5Prime Hot Master Mix Taq polymerase (5Prime; Gaithersburg, MA), a modified
polymerase from Qiagen (Valencia, CA) was employed using the same reaction
parameters.

Statistical analysis
Calculations for qPCR data involved converting cycle threshold (Ct) values to
fold-change between control and autism donors using the 2-ΔΔCT method by Livak and
Schmittgen (Livak & Schmittgen, 2001). Endpoint PCR data was computed as relative
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values generated from the ratios of amounts of target gene expression to the average of
two reference gene expressions. Afterwards, both data from qPCR and endpoint PCR
were analyzed by the paired Student t-test. Statistical results are reported before and
after Holm’s Bonferroni correction (Gaetano, 2014; Holm, 1979) for the number of
comparisons as noted in the results below. Pearson’s correlation was used to
determine possible effects of postmortem variables (age, RIN, and PMI) on the
expression of each gene. Given the number of correlation tests, a p<0.01 was chosen a
priori to indicate statistical significance in order to reduce type I errors.

Results
Glutamate-related gene expression.
The levels of expression of 7 ionotropic glutamate receptor subunit genes
(GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIK2, GRIA1) and two metabotropic
glutamate receptor genes (GRM5, GRM8) were measured in BA24 pyramidal neurons
and surrounding astrocytes from ASD and age-matched control donors. GRM8
expression was not detectable in astrocytes. Levels of GRM8 expression were
modestly lower in pyramidal neurons from ASD donors compared to matched control
donors (t=2.89; p=0.034), but statistical significance was lost when the p value was
corrected for the number of matched pair comparisons of gene expressions in neurons
(Table 3.2). No other differences in the levels of expression of any glutamate receptor
gene were observed in either pyramidal neurons or astrocytes comparing ASD to
control donors (Figure 3.2).
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Figure 3.2. Levels of expression of ionotropic glutamate receptor subunits and
metabotropic glutamate receptors.
Expression of glutamate receptors and receptor subunits was measured in laser
captured BA24 pyramidal neurons and separately in surrounding astrocytes of typically
developing control donors (open symbols) and ASD donors (closed symbols). Gene
expression levels are normalized to the averaged levels of expression of references
genes (GAPDH and Ribo18S1). Mean values are noted by horizontal lines and
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statistical significance (uncorrected for the number of comparisons) is noted above the
data points.

Table 3.2. Results of Holm-Bonferroni Sequential Correction of
multiple paired Student’s t-tests of gene expression data from BA24 neurons.
Gene (protein)
RNA18S1 / GAPDH
GRIN1 (NR1)
GRIN2A (NR2A)
GRIN2B (NR2B)
GRIN2C (NR2C)
GRIN2D (NR2D)
GRIA1 (GluR-1)
GRIK2 (GRIK2, GluK2)
GRM5 (mGluR5)
GRM8 (mGluR8)
SLC1A1 (EAAT3)
SLC17A7 (VGlut1)
GRIP1 (GRIP1)
BDNF (BDNF)
NTRK2 (NTRK2,TrkB)
a

P value from
Paired t-test
0.3774
0.0533
0.9051
0.1160
0.9924
0.1146
0.2424
0.3793
0.1061
0.0340
0.0235
0.5034
0.0064
0.4846
0.0006

P’ from
correctiona
1.000
0.583
1.000
1.000
1.000
1.000
1.000
1.000
1.000
0.408
0.312
1.000
0.090
1.000
0.009

Significance?
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes

Holm-Bonferroni corrected p value

Additional genes associated with glutamatergic neurotransmission were
interrogated in BA24 pyramidal neurons and astrocytes, including glutamate transporter
genes, SLC1A1, SLC1A2, SLC1A3, SLC17A7, and the glutamate receptor interacting
gene, GRIP1. Of these genes, the expression of astrocyte-associated transporter
genes SLC1A2 and SLC1A3 was not measured in neurons and the neuronal glutamate
transporter gene SLC1A1 was not measured in astrocytes. Levels of SLC1A1 (t= 2.88;
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p=0.024) and GRIP1 (t=3.84; p =0.006) gene expression were lower in pyramidal
neurons captured from ASD donors as compared to matched control donors (Figure
3.33). However, statistical significance was lost when p values were corrected for the
number of matched pair comparisons (Table 3.2). No significant differences in the
levels of expression of any of the glutamate-related genes, SLC1A2, SLC17A7, and
GRIP1, were observed in astrocytes comparing ASD to matched control donors (Figure
3.3).

Figure 3.3. Levels of expression of glutamate transporter genes and a glutamate
receptor interacting gene.
Gene expression was measured in laser captured BA24 pyramidal neurons and
separately in surrounding astrocytes of typically developing control donors (open

65	
  

	
  
symbols) and ASD donors (closed symbols). Gene expression levels are normalized to
the averaged levels of expression of references genes (GAPDH and Ribo18S1). Mean
values are noted by horizontal lines and statistical significance (uncorrected for the
number of comparisons) is noted above the data points.

BDNF/NTRK2.
Levels of expression the neurotrophic factor gene BDNF and its receptor gene
NTRK2 were measured in pyramidal neurons and astrocytes from BA24 (Figure 3.4).
BDNF expression in both neurons and astrocytes was similar comparing ASD to
matched control donors. However, NTRK2 expression levels were robustly lower in
pyramidal neurons (t=5.87; p=0.0006), but not astrocytes, from ASD donors as
compared to control donors. The difference in NTRK2 expression levels between ASD
and control donors remained statistically significant after correction for the number of
matched comparisons (Table 3.2).
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Figure 3.4. Levels of expression of BDNF and its receptor gene NTRK2.
Gene expression was measured in laser captured BA24 pyramidal neurons and
separately in surrounding astrocytes of typically developing control donors (open
symbols) and ASD donors (closed symbols). Gene expression levels are normalized to
the averaged levels of expression of references genes (GAPDH and Ribo18S1). Mean
values are noted by horizontal lines and statistical significance (uncorrected for the
number of comparisons) is noted above the data points.

Expression of selected genes in BA10.
The expression levels of four genes were studied in BA10 pyramidal neurons
from ASD and control donors. Chosen for study were those genes analyzed in BA24
pyramidal neurons that demonstrated either no difference (GRM5), marginal or modest
differences (GRIN1, SLC1A1) or highly significant differences (NTRK2) comparing ASD
to control donors as noted above. In this set of experiments, BA10 tissue from one agematched pair of donors used in the BA24 studies above was not available; BA10 tissue
from one different age-matched pair of donors was substituted as noted in Table 3.1.
The expression levels of each of these four genes in laser captured pyramidal neurons
from BA10 were similar in ASD and matched controls (Figure 3.5; GRIN1 t=0.74,
p=0.49; GRM5 t=0.90, p=0.40; SLC1A1 t=0.26, p=0.80; NTRK2 t=0.03, p=0.97).
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Figure 3.5. Levels of expression of GRM5, GRIN1, SLC1A1, and NTRK2 in
pyramidal neurons of BA10.
Gene expression was measured in laser captured BA10 pyramidal neurons from
typically developing control donors (open symbols) and ASD donors (closed symbols).
Gene expression levels are normalized to the averaged levels of expression of
references genes (GAPDH and Ribo18S1). Mean values are noted by horizontal lines.
No statistically significant differences were observed.

Demographic variables, reference genes, and tissue factors.
There were no statistical differences between ASD and matched control donors
of BA24 tissue regarding age, RIN, or PMI values (Table 3.1). Likewise, there were no
differences in these variables comparing groups of donors of BA10 tissue (Table 3.1).
There were no significant correlations between age or PMI and any of the 15 gene
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expressions measured in BA24 pyramidal neurons (Table 3.3). There was a significant
correlation between levels of GRIN2C expression and RIN values, but there were no
other correlations between RIN and the levels of any mRNA that was studied in BA24
pyramidal neurons. In BA24 astrocytes, age correlated significantly with NTRK2 gene
expression levels (p=0.002), but not with levels of any other gene (Table 3.4). RIN did
not significantly correlate with expression levels of any gene in BA24 astrocytes, while
PMI correlated with only SLC17A7 gene expression in BA24 astrocytes (Table 3.4). In
BA10 pyramidal neurons, there were no significant correlations between age, RIN, or
PMI and the levels of expression of any of the target or reference genes (Table 3.5).
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Table 3.3. Pearson’s correlation analyses for possible relationships between gene
expression levels in BA24 neurons and age, RNA quality (RIN) and postmortem interval
(PMI).
a

b

Gene (protein )
RNA18S1 / GAPDH

c

GRIN1 (NR1)
GRIN2A (NR2A)
GRIN2B (NR2B)
GRIN2C (NR2C)
GRIN2D (NR2D)
GRIA1 (GluR-1)
GRIK2 (GRIK2, GluK2)
GRM5 (mGluR5)
GRM8 (mGluR8)
SLC1A1 (EAAT3)
SLC17A7 (VGlut1)
GRIP1 (GRIP1)
BDNF (BDNF)
NTRK2 (NTRK2,TrkB)

Statistic
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

Age
-.309
.243
16
.050
.855
16
-.055
.851
14
.109
.687
16
.229
.394
16
.322
.224
16
-.374
.154
16
-.316
.233
16
-.017
.953
15
.131
.684
12
-.191
.478
16
.003
.991
16
-.128
.638
16
.005
.985
16
.522
.038
16
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RIN
.043
.875
16
.318
.231
16
.531
.051
14
.579
.019
16
d
.642
.007
16
.082
.763
16
.213
.429
16
.250
.350
16
-.117
.677
15
.140
.664
12
.285
.284
16
.312
.240
16
.265
.320
16
-.084
.757
16
.271
.310
16

PMI
-.250
.350
16
-.226
.400
16
.176
.548
14
-.250
.351
16
-.091
.737
16
.203
.452
16
-.012
.966
16
-.346
.189
16
-.435
.105
15
.029
.929
12
-.591
.016
16
-.358
.173
16
-.030
.913
16
-.212
.430
16
-.076
.780
16

	
  
Table 3.4. Pearson’s correlation analyses for possible relationships between
gene expression levels in BA24 astrocytes and age, RNA quality (RIN) and
postmortem interval (PMI).
Genea (proteinb)

Statistic
Pearson Correlation
RNA18S / GAPDHc
Sig. (2-tailed)
N
Pearson Correlation
GRIN1 (NR1)
Sig. (2-tailed)
N
Pearson Correlation
GRIN2A (NR2A)
Sig. (2-tailed)
N
Pearson Correlation
GRIN2B (NR2B)
Sig. (2-tailed)
N
Pearson Correlation
GRIN2D (NR2D)
Sig. (2-tailed)
N
Pearson Correlation
GRIA1 (GluR-1)
Sig. (2-tailed)
N
Pearson Correlation
GRM5 (mGluR5)
Sig. (2-tailed)
N
Pearson Correlation
SLC1A3 (EAAT1)
Sig. (2-tailed)
N
Pearson Correlation
SLC1A2 (EAAT2)
Sig. (2-tailed)
N
Pearson Correlation
SLC17A7 (vGlut1)
Sig. (2-tailed)
N
Pearson Correlation
GRIP1 (GRIP1)
Sig. (2-tailed)
N
Pearson Correlation
BDNF (BDNF)
Sig. (2-tailed)
N
Pearson Correlation
NTRK2 (NTRK2, TrkB)
Sig. (2-tailed)
N

71	
  

Age
.074
.786
16
.092
.736
16
.282
.290
16
.523
.038
16
.547
.028
16
-.046
.865
16
.577
.019
16
-.340
.197
16
-.101
.711
16
-.470
.066
16
-.086
.751
16
.479
.060
16
.711d
.002
16

RIN
.119
.662
16
.133
.624
16
.516
.041
16
.520
.039
16
.395
.130
16
.490
.054
16
.328
.216
16
-.238
.375
16
.023
.932
16
.214
.426
16
-.146
.590
16
-.153
.571
16
.123
.649
16

PMI
.443
.085
16
-.003
.991
16
-.116
.670
16
-.060
.826
16
.227
.398
16
.009
.975
16
.112
.679
16
-.344
.192
16
-.186
.491
16
-.655d
.006
16
.378
.149
16
.492
.053
16
.187
.488
16

	
  
Table 3.5. Pearson’s correlation analyses for possible relationships between gene
expression levels in BA10 neurons and age, RNA quality (RIN) and postmortem interval
(PMI).
Genea (proteinb)
RNA18S1 / GAPDHc

GRIN1 (NR2A)

GRM5 (mGluR5)

SLC1A1 (EAAT3)

NTRK2 (NTRK2, TrkB)

Statistic
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

Age
-.122
.653
16
.114
.675
16
.328
.215
16
-.105
.722
14
-.234
.420
14

RIN
-.407
.148
14
.415
.140
14
.228
.432
16
.659
.020
12
.537
.072
12

PMI
.002
.995
14
.059
.841
14
.088
.765
14
.282
.374
12
-.094
.773
12

Reference genes were carefully chosen as those that were stable in their
expression levels across the two groups of subjects. The ratios of levels of expression
of RNA18S1 and GAPDH were not significantly different in laser captured BA24
neurons (t = 1.00, p = 0.35), BA24 astrocytes (t = 0.93, p = 0.38), or BA10 neurons (t =
1.82, p = 0.11) comparing ASD and matched control donors (Figure 3.6).
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Figure 3.6. Ratio of reference gene expression levels.
Gene expression was measured for GAPDH and Ribo18S1 in typically developing
control donors (open symbols) and ASD donors (closed symbols). The ratio of gene
expression between the two reference genes was compared for control and ASD
subjects for BA24 neurons and astrocytes and BA10 neurons to ensure that the
reference genes had stable expression levels between the groups. No statistically
significant differences were observed.

It should be noted that we wished to screen multiple brain regions for these gene
expression changes to determine the extent to which they occurred in the brain.
Because LCM is time-intensive and expensive, we attempted to measure SLC1A1,
GRIP1, NTRK2 expression in RNA isolated from homogenates of ACC. However, we
were unable to detect any differences in expression of these genes in RNA isolates
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from homogenates of ACC, using tissues collected from seven of the eight ASD –
control donor pairs that were used for the LCM study above (Figure 3.7). To verify the
stability of reference gene expression levels across the two groups of subjects, the
ratios of GAPDH and TATA expression were examined and were not found significantly
different when comparing ASD and matched control donors (t = 0.19, p = 0.86) (Figure
3.8).

Figure 3.7. Levels of expression of SLC1A1, GRIP1, and NTRK2 in punchdissected BA24 gray matter.
Gene expression was measured in typically developing control donors (open symbols)
and ASD donors (closed symbols) using RNA isolated from homogenates of puncheddissected gray matter rather than specific laser captured cells as shown in Figures 1-5.
Gene expression levels were determined by real time PCR and are normalized to the
geometric mean of stable references genes (GAPDH and TATA). No statistically
significant differences were observed.
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Figure 3.8. Ratio of reference gene expression levels for qPCR.
Gene expression was measured for GAPDH and TATA in typically developing control
donors (open symbols) and ASD donors (closed symbols). The ratio of gene
expression between the two reference genes was compared for control and ASD
subjects for BA24 punch-dissected gray matter tissue samples to ensure that the
reference genes had stable expression levels between the groups. No statistically
significant difference was observed.

Four of the ASD donors had been prescribed psychotherapeutic medications,
with three of the four receiving SSRI antidepressants and four of the four receiving
antipsychotic drugs (see Table 3.1). Considering that effects of psychotherapeutic
drugs might contribute to observed differences in gene expression in BA24 neurons as
shown above, a comparison was made of antidepressant/antipsychotic exposed ASD
donors to ASD donors not exposed to these drugs. Albeit the sample sizes of these two
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groups are small and that these two subgroups were not matched for age and other
demographic variables, there were no significant difference in levels of GRM8 (unpaired
t-test; t=0.17, p=0.87), GRIP1 (0.01, p=0.99), SLC1A1 (t=0.28, p=0.79), NTRK2 (t=0.59,
p=0.57) comparing antidepressant/antipsychotic exposed ASD donors to ASD donors
without these drugs.

Discussion
This study examined the expression of genes involved in glutamatergic
neurotransmission in ASD. We found modestly low levels of expression of genes
encoding a glutamate receptor (GRM8), glutamate transporter (SLC1A3), and a
glutamate receptor anchoring protein (GRIP1), and a robust reduction in expression of a
neurotrophin receptor gene (NTRK2) in pyramidal neurons dissected by LCM from ACC
tissue of donors with ASD when compared to typically developing controls. This is the
first study to use LCM to isolate a specific cell population to examine the molecular
pathology of ASD. The use LCM to capture distinct cell populations provided cellular
resolution to the assessment of pathology, and permitted identification of gene
expression changes that we were unable to detect using homogenates of the same
brain region in the same subjects. The difference in the results of LCM of single cell
populations versus homogenates of tissues is likely the result of overlapping gene
expression in other unaffected cell types that in essence dilute cell-specific gene
expression changes, as has been demonstrated in research on Alzheimer’s disease
(Ginsberg & Che, 2005; Ginsberg et al., 2004). The gene expression deficits identified
in the present study were restricted to ACC pyramidal neurons and not found in
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surrounding astrocytes in the same brain region, or in pyramidal neurons in BA10 of the
prefrontal cortex, suggesting the presence of a cell- and region-specific pathology in
ASD.
Cells used for this study were dissected from the neocortical layer III of the ACC
where both changes in cell size and packing density have been demonstrated
previously (Simms et al., 2009). Also, mini-column disturbances i.e. reduced column
width and increased column number have been shown in the ACC with pyramidal
neurons demonstrating misalignment (Casanova et al., 2002). An increase in spine
density of pyramidal neurons in frontal, parietal and temporal lobes has been reported
for ASD (Avino & Hutsler, 2010), although the ACC has not been studied to date. The
present study identifies specific gene expression abnormalities in glutamatergic
pyramidal cells and adds to the growing body of literature that implicates these
excitatory neurons in the complex pathobiology of autism.
A recent study demonstrated that neurons, not glia, from the neocortex of
multiple brain regions exhibited decreased gene expression that indicated abnormal
columnar architecture within all six cortical layers that the authors referred to as
“patches” (Stoner et al., 2014). The authors of these data acknowledge that they have
uncovered a unique ASD cortical pathology involving several genes that are found in
multiple cell types, (Stoner et al., 2014); but no mechanism of pathogenesis is known.
In addition, an elevated number of neurons has been detected in layer VI of the ASD
ACC indicating that incomplete migration of neurons may have occurred during
development (Simms et al., 2009). Our studies have identified abnormal gene
expression in pyramidal neurons, but not glia, that could contribute to abnormal
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columnar structure in the neocortex in autism.
A striking finding of this study was the decreased expression of the growth factor
receptor gene NTRK2B in ACC pyramidal neurons from ASD donors. This gene
encodes the high-affinity tyrosine kinase B receptor, TrkB, the ligand for which is BDNF,
NT-3 and NT-4/5 (Klein et al., 1991; Klein, Lamballe, Bryant, & Barbacid, 1992). TrkB
signaling is of critical importance to cell function, with ligand-activated TrkB engaging
several intracellular signaling pathways including MAPK, PI3, and ERK that are
important in neurotransmission, plasticity and differentiation (Boulle et al., 2012).
Several laboratories have reported elevated peripheral and central BDNF levels in ASD
(Connolly et al., 2006; Correia et al., 2010; Miyazaki et al., 2004; Nelson et al., 2006;
Perry et al., 2001). A genetic association between polymorphisms of NTRK2 and ASD
has also been identified (Correia et al., 2010). It seems unlikely that a functional
polymorphism NTRK2 that might account for the observed reduction in NTRK2
expression in pyramidal cells since one would expect NTRK2 gene expression to be
similarly affected in astrocytes and pyramidal neurons in other brain regions. Of the
cells that we studied, we found the reduction of NTRK2 only in ACC pyramidal neurons.
Interestingly, the most strongly associated polymorphisms in ASD were found in the
intron-spanning regions of NTRK2, which could reflect aberrant transcriptional
mechanisms under cell-specific control in ASD. Mouse knock out (KO) models indicate
that NTRK2 deficient mice die soon after birth (Klein et al., 1993; Rohrer et al., 2004).
However, mice with a conditional loss of NTRK2 expression exhibit a wide variation in
behavior ranging from social deficits to antisocial behavior (as reviewed by Lindholm &
Castrén, 2014). Interestingly, the TrkB receptor in BDNF conditional KO mice develop
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BDNF-independent signaling mechanisms (Di Lieto et al., 2012). It is noteworthy that
the BTBR mouse model for ASD exhibits reduced TrkB protein expression (Scattoni,
Martire, Cartocci, Ferrante, & Ricceri, 2013). Defective TrkB signaling has been shown
in Angelmann (Cao et al., 2013) and Fragile X (Uutela et al., 2014) mouse models, both
of which are syndromes with a high incidence of autistic features. The present study
provides further support for a role of BDNF/TrkB in ASD, specifically providing evidence
of reduced NTRK2 gene expression in ACC pyramidal neurons.
Gene expression changes in synapse-related genes have been demonstrated in
disorders that have autistic features such as Angelmann Syndrome and Fragile X
Syndrome (as reviewed by Ebert & Greenberg, 2013). Abnormalities in
neurotransmitter signaling networks are likely to be a core component of the cellular
neurobiology of ASD. We chose to interrogate potential expression changes in several
genes associated with excitatory amino acid cell signaling in autism. Three of these
genes, SLC1A1, GRIP1, and GRM8, demonstrated trends toward reduced expression
in ACC pyramidal neurons in ASD. SLC1A1 is responsible for glutamate uptake from
the synapse by pyramidal neurons while GRIP1 anchors AMPA receptors to the cell
membrane. GRM8 inhibits the adenylyl cyclase/cAMP pathway and decreases the
likelihood of cell death associated with excess NMDA signaling (Ambrosini, Bresciani,
Fracchia, Brunello, & Racagni, 1995). The decreased expression of GRM8 receptor in
ASD, if accompanied by reduced GRM8 receptor, could leave pyramidal cells
susceptible to neurotoxic effects of elevated glutamate signaling through the NMDA
receptor. This neurotoxic effect could be amplified further if reduced SLC1A1
expression observed in ASD results in less glutamate transporter activity at the
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glutamatergic synapse, thereby further increasing glutamate activation of NMDA
receptors on these pyramidal neurons. Reduced GRIP1 expression, as we observed in
ASD, could be a compensatory mechanisms to override excess NMDA receptor
activation by glutamate. Whatever the exact sequence or consequence, abnormal
expression levels of these genes implies that excitatory output from the ACC via
pyramidal neurons is disrupted in ASD. Because GRIP1 and NTRK2 is expressed by
multiple cell types, it cannot be dismissed that these glutamatergic-related gene
expression decreases are only found in excitatory cells. While we did not find GRIP1 or
excitatory transporter changes (SLC1A2 and SLC1A3) in the glia cells studied herein,
altered expression of these genes could occur in inhibitory neurons of the ACC, which
were not studied. Nevertheless, any disruption of glutamate transmission and function
implicates a compromise in the delicate balance of inhibitory and excitatory neuronal
activity of the ACC. Future studies need to include a more detailed examination of gene
expression in other cell types of the ACC.

Limitations
There were several limitations in the current study that should be taken into
consideration. First, like many studies of ASD relying on postmortem brain tissue, the
number of donors available was limited and reduced the power of the study. It should
be noted that all donors that had a history of seizure disorder were excluded from the
study to reduce experimental variability. Our laboratory has observed that the use of
LCM to isolate distinct cell populations results in reduced variability of data, permitting
the use of smaller sample sizes to obtain statistical significance. ASD is a highly
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heterogeneous disorder and there were not enough brain donors to permit us to
examine the gene expressions in subgroups of donors based on clinical presentation.
Changes in gene expression do not always correlate with changes in the expression of
the cognate protein, and often a change in gene expression is not temporally correlated
with changes in the cognate proteins. Hence, whether reduced NTRK2B expression in
ASD pyramidal neurons results in lower TrkB protein in these cells is not currently
known. Nevertheless, altered levels of NTRK2B expression in ASD is highly suggestive
of perturbed TrkB signaling in ASD. ASD donors used in the present study were
exposed to psychotherapeutic drugs that could alter gene expression, particularly
selective serotonin uptake inhibitor (SSRIs) and risperidol, an atypical antipsychotic.
But, repeated administration of the antidepressants tranylcypromine, sertraline, or
desipramine to rats increases NTRK2 expression (Nibuya, Morinobu, & Duman, 1995).
Hence, reduced NTRKB expression in the present study is unlikely to reflect previous
antidepressant drug therapy. Repeated treatment of rats with ripseridol produced no
change in TrkB immunoreactivity in the brain (Angelucci, Mathé, & Aloe, 2000), again
suggesting that psychotherapeutic drug exposure is not a likely mediator of reduced
NTRK2 expression in ASD in the present study. Findings herein demonstrate no
obvious effect of psychotherapeutic drug exposure on NTRK2 (or GRM8, GRIP1,
SLC1A1) expression. Tissue-related physical factors were considered as possible
sources of variance in these experiments. However, there were no significant
differences between ASD and control donor samples when comparing age, RNA quality
(RIN), postmortem intervals (Table 3.1).

81	
  

	
  

Conclusions
Multiple gene abnormalities are significantly associated with ASD (Betancur,
2011). It therefore seems likely that multiple etiologies exist that can result in ASD.
Brain pathology is downstream to gene polymorphisms and etiologies, and more
proximal to the pathophysiology underlying the abnormal behaviors. Hence, the
neuropathology of autism may be more limited in terms of variability than the genotypes
that can contribute to it, i.e. different etiologies may result in a similar
structural/neurochemical abnormality that disrupts function to produce a specific set of
behavioral abnormalities. The present study was designed to examine possible
disruption of a key neuronal unit, the glutamatergic pyramidal neuron, of the ACC in
ASD. The data presented here reveals strong evidence of disrupted neurochemistry of
ACC pyramidal neurons, specifically involving glutamatergic neurotransmission and
neurotrophic factor (BDNF) signaling through the TrkB receptor. It is tempting to
speculate that abnormalities in ACC as revealed in imaging studies of ASD patients are
at least partially the result of deficits in pyramidal neuronal function in the ACC as
revealed in the present study. Pyramidal neurons in layer III of the ACC synapse with
other cortical neurons including inhibitory neurons and long-range pyramidal motor
neurons in layer V and the present findings suggest that neural communication with
these other brain areas or pathways is altered in ASD. Interestingly, pyramidal neurons
take years to reach maturity, possibly well into adolescence (Huttenlocher, 1970),
indicating that normal neural development of this cell type may be especially vulnerable
to deleterious environmental influences occurring early in life.
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CHAPTER 4
RNA-SEQ ANALYSIS OF LASER CAPTURED SAMPLES FROM ANTERIOR
CINGULATE CORTEX OF MALES WITH AUTISM SPECTRUM DISORDER

Introduction
Ginsberg et al (Ginsberg, Alldred, & Che, 2011) have shown significant
disparities between gene expression differences found using homogenate brain
samples versus laser captured single cell populations from the same tissues. The
Ginsberg study used microarrays to examine the brains of control and Alzheimer’s
disease (AD) subjects. Microarray data from CA1 captured cell populations displayed a
dissimilar gene expression profile compared to the data obtained from hippocampal
homogenate samples. Genes found to be essential for the dysfunction of CA1 neurons
in AD were not found significantly altered in the homogenate samples. We have also
observed different findings depending on whether tissue contains multiple or single cell
types (compare Figures 3.7 and 3.4 for NTRK2 expression). These findings
demonstrate the need to focus gene expression profiling on single cell populations in
order to achieve a better understanding of the biochemical and cellular basis of
pathology.
Within the ASD research field to date, molecular pathology studies used brain
samples that contain multiple cell types. The results of these studies have been
insufficient to formulate a theoretical etiology of the disease. ASD is a spectrum of
disorders with patients exhibiting vast differences in symptom presentation. By using an
approach targeted at molecular pathology within a single cell population, a common
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cellular dysfunction might be found that could unify our conceptualization of ASD brain
pathology throughout the spectrum. Identification of key cellular abnormalities could
result in the development of novel targeted treatments for ASD. In this study, LCM was
used to obtain clusters of multiple cell types and separately, selected cell populations.
Using these samples, I attempted to development experimental protocols to permit gene
expression profiling using RNA-Seq technology. Ultimately, I hoped to identify specific
gene expression abnormalities in specific cell populations to further our understanding
of ASD pathology. However, the experimental approach of combining LCM of single
cell populations with RNA-Seq, was a first in the field with no published study known to
us to date. Therefore, first and foremost was the determination of the feasibility of the
approach.
RNA-Seq provides in-depth transcriptome analysis that cannot be achieved using
methods such as microarrays, providing information regarding splicing variants,
transcriptional start points, and rare RNA isoforms. RNA-Seq permits researchers to
explore all levels of transcriptional regulation in the cell (Nagalakshmi, Waern, &
Snyder, 2010; Wang, Gerstein, & Snyder, 2009; Wilhelm & Landry, 2009). This type of
analysis has the potential to bring light to unanswered questions of ASD pathology, and
also to establish a novel method to investigate the contributory roles of different brain
cell types in neurological diseases. Data generated herein will be made available for
mining in future studies, although it is likely that samples in addition to those that I have
now analyzed will be needed to enhance the statistical power of the study. 	
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Methods
Brain Tissue
Frozen tissue blocks containing BA24 from six ASD donors and nine typically
developed control donors were obtained from Autism Tissue Program, Harvard Brain
Tissue Resource Center (Belmont, MA) and NICHD Brain and Tissue Bank for
Developmental Disorders (Baltimore, MD) (Table 4.1). This study was reviewed and
approved for exemption by the Institutional Review Board of East Tennessee State
University under the Department of Heath and Human Services exemption 45 CFR
46.101(b) relating to the use of publicly available unidentifiable pathology specimens.
ASD and control donors were matched prior to experimentation as closely as possible
by age primarily, but also by RNA quality (Table 4.1), to reduce the impact of these
factors from the two groups. ASD donors met diagnostic criteria outlined in the
Diagnostic and Statistical Manual (DSM) IV for autistic disorder. The Autism Diagnostic
Interview-Revised (ADI-R) and other medical records were also used to confirm
diagnoses. Causes of death and comorbidities are not included in Table 4.1 to protect
the identities of the decedents. Cause of death for typically developed control donors
included drowning (3 donors), motor vehicle accident (2 donors), asphyxia (1 donor),
abdominal injuries (1 donor), and heart attack (1 donor). Cause of death for ASD
donors included acute respiratory distress syndrome (1 donor), cancer (1 donor),
drowning (1 donor), head trauma (1 donor), diabetic ketoacidosis (1 donor), and bowel
obstruction (1 donor).
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Table 4.1. Subject demographic information.
Age

Gender

RINa

PMI
(hours)b

Toxicology

Sample

AN14757

24

M

7.8

21.33

No drugs reported

WMd, Neuron

AN07444

17

M

7.5

30.75

Sertraline

WM

5408

6

M

7

16

No drugs reported

WM, Neuron

4848

16

M

7.6

15

No drugs reported

Neuron

5342

22

M

8.1

14

No drugs reported

WM

5079

33

M

7.3

16

Ethanol

WM

M3231M

37

M

7.4

24

No drugs reported

WM, Neuron

4337

8

M

8.4

16

No drugs reported

WM

ID
Controls

MEAN

20.38

7.64

19.14

SEM

3.88

0.16

2.05

ASD
AN04166

24

M

8.1

18.51

No drugs reported

WM, Neuron

AN02987

15

M

6.5

30.83

No drugs reported

WM

5144

7

M

8

3

WM, Neuron

5302

16

M

6.6

20

5027

37

M

7.7

26

4721

8

M

6.1

16

No drugs reported
Risperidone,
Fluvoxamine,
Clonidine, Insulin
Risperidone,
Fluvoxamine
No drugs reported

7.17

19.06

MEAN

17.83

Neuron
WM, Neuron,
Astrocyte
WM

SEM

4.59
0.35
3.90
P value
0.68
0.26
0.99
a
RNA integrity number (index of RNA quality)
b
Postmortem interval
c
Results of a two-tailed independent t-test comparing control and ASD groups.
d
White matter
g

Tissue Preparation and Laser Capture Microdissection
Superficial white matter was laser captured from BA24 brain sections (10 µm
thickness) mounted on PEN membrane glass slides (Life Technologies, Grand Island,
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NY). In order to identify cell types as well as key tissue structures and white or gray
matter type, the tissue sections were stained using Histogene LCM Frozen Section
Staining Kit (Life Technologies, Grand Island, NY) according to the manufacturer’s
instructions. Superficial white matter was defined as the white matter area directly
adjacent to gray matter and within 3 mm of the white/gray matter border area. Multiple
large circular areas were captured for each sample.
Pyramidal neurons and white matter astrocytes were stained and captured from
BA24 cortical layer 3 using the methods previously described in Chapter 3. Enough
cells were captured per samples to be able to prepare a RNA-Seq library (1000 neurons
and 2000 astrocytes per subject) and to synthesize cDNA for PCR confirmation (500
neurons). Captured cells were incubated at 42°C for 30 min in the extraction buffer
provided in the RNA isolation kit.

RNA-Seq Library Preparation
RNA was isolated from the captured samples using PicoPure RNA Isolation Kit
(Life Technologies, Grand Island, NY) with the additional RNase-free DNase kit
(Qiagen, Valencia, CA) step outlined in the manufacturer’s protocol. RNA quality and
quantity were assessed using the Agilent RNA 6000 Pico kit (Agilent Technologies,
Santa Carla, CA). The Ovation Single Cell RNA-Seq System (NuGEN, San Carlos, CA)
was used to generate RNA-Seq libraries from isolated RNA. An input amount of over
100 pg of starting RNA was used for each library sample. Two forms of library quality
check were used before library pooling. Total quantity of library produced and fragment
length was assessed using the Agilent High Sensitivity DNA Kit (Agilent Technologies,
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Santa Carla, CA). This method quantified all library fragments produced. The KAPA
Library Quantification Kit (KAPA Biosystems, Woburn, MA) was used to determine the
amount of correctly made library that would be able to bind to the sequencing flow cell.
This kit is a PCR based assay that determines the concentration of library using primer
for the P5 and P7 sequencing adaptors for the Illumina platform. The assay included a
six point serial dilution standard series that assisted in determining reaction efficiency
and concentrations of samples.

Library Pooling
Each library created was uniquely barcoded with a unique sequence of DNA
during the library preparation step. This barcode allows multiple samples to be
sequenced within one flow cell. The generated data can then be sorted for individual
samples based on this unique barcode sequence. Since there is no method for
downstream normalization for library input amounts in a pooled sample, it is imperative
that each individual library be equally represented by concentration in the pooled library.
The sample concentrations determined by the KAPA PCR quantification assay were
used to standardize input amounts.

RNA-Seq
Pooled libraries were sent to David H. Murdock Research Institute for
sequencing. Prior to sequencing, another PCR based quantification was performed on
the pooled library sample to ensure that cluster density on the flow cell would be
optimal. A cBot instrument (Illumina, San Diego, CA) was used to perform cluster
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amplification on the flow cell before sequencing. The HiSeq2500 instrument (Illumina,
San Diego, CA) was used for 100 base paired reads with indexing sequencing using the
instrument’s high output sequencing run.

Bioinformatics Analysis
Following sequencing, base calling was performed with CASAVA (v1.8.2)
(Illumina, San Diego, CA). Filtering and trimming of reads consisted of removal of
Illumina Adapter Library and trimming using the following parameters (quality score
limit: 0.05, trim ambiguous nucleotides: <2 and removed 15 bp from the 5’ and 5 bp
from the 3’ end respectively) in the CLC Genomics Workbench 7.0.4 (Qiagen, Valencia,
CA). The resulting read length averaged ~80 bp. Reads were then aligned to the
human genome (latest version, hg38/GRCh38, assembled on December 2013,
annotations updated in June 2014) using CLC Genomics Workbench 7.0.4 using the
CLC’s RNA-Seq package (Mismatch cost = 2, Insertion cost = 3, Deletion cost = 3,
Length fraction = 0.8, Similarity fraction = 0.8). To determine differentially expressed
genes, a Kal’s Z-test (Kal et al., 1999) was performed for comparison within pairs.
Baggerly Beta-binomial test (Baggerly, Deng, Morris, & Aldaz, 2003) was performed for
group comparisons using the control donors as the reference. A false discovery rate
(FDR) correction was used to further correct p-values achieved using the above
proportion-based tests. We used both paired and unpaired statistical comparisons of
control and autism gene expressions for these preliminary data understanding that with
the small sample size, neither approach is likely to produce data with high statistical
confidence.
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PCR Confirmation
RNA was isolated from the captured samples using PicoPure RNA Isolation Kit
(Life Technologies, Grand Island, NY) with the additional RNase-free DNase kit
(Qiagen, Valencia, CA) step outlined in the manufacturer’s protocol. RNA samples
were reverse transcribed into cDNA using the Superscript III kit (Life Technologies;
Grand Island, NY) that contained oligodT and random hexamer primers. Gene specific
primers were purchased from a vendor (Qiagen; Valencia, CA). Gene primer
sequences are shown in Appendix B. To quantify transcripts, endpoint PCR was used
for RNA isolated from laser captured cells as previously described (Ordway et al., 2009;
Xiang et al., 2008). Endpoint PCR data was computed as relative values generated
from the ratios of amounts of target gene expression to a reference gene. Afterwards,
endpoint PCR data were analyzed by the paired Student’s t-test.

Results
Sequencing Quality Based on Phred Score
The first step in the analysis of sequencing is base-calling. This process consists of
taking the multiple single nucleotide reads and composing the sequence of the fragment
clusters. Using the Phred scoring methods, a cut-off score of around 30 is considered
an acceptable quality for base-calling. A Phred score of 30 translates to a 1 in 1000
probability of an incorrect base-call or a 99.9% accuracy in sequence detection (B.
Ewing, Hillier, Wendl, & Green, 1998; Brent Ewing & Green, 1998). The PHRED score
for all samples (white matter, neuron, and astrocyte preparations) exceeded this cut-off
by reaching an average score of 35 to 40. A score of 40 translates to a probability of 1
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in 10,000 incorrect base-call or a 99.99% accuracy in detection.

Mapping and Alignment
Mapping Percent and Total Reads. The three types of sample preparations,
white matter containing mixed populations of cells, pyramidal neurons, and GFAPpositive astrocytes, were compared to determine if there was a difference in mapping
percentages based on sample type. There was no significant effect of sample type on
the type of read produced by the samples (Figure 4.1). White matter and neuron
samples were further analyzed to determine if there was a difference in the mapping
between control and ASD subject samples. No difference was found between control
and ASD samples for white matter (Figure 4.2A, p = 0.64) or neuron (Figure 4.2B, p =
0.63) preparations.

Figure 4.1. Division of read types of the white matter, neuron, and astrocyte RNA-Seq
samples. The percent of reads mapped in pairs (white bars), mapped in broken pairs
(shaded bars), and reads not mapped (black bars) were plotted as a percent of total
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reads for all samples.

Figure 4.2. Comparison of read mapping between control and ASD samples for white
matter (A) and neurons (B). The percentage of total mapped reads (mapped in pairs
and broken pairs) of total reads was plotted. No significant difference was found
between control and ASD samples for white matter or neuron samples.

Paired Read Mapping. For reads that were mapped as pairs, an analysis was
done to investigate where those reads aligned (Figure 4.3). Approximately 75% of all
mapped paired reads aligned to intron regions for all sample preparations. This was
also the case when examining the alignment pattern between control and ASD samples
for white matter (Figure 4.4A) and neuron (Figure 4.4B) sample preparations. To
ensure that observed intronic read mapping was in agreement with previously reported
brain sample RNA-Seq data, the percentage of intron reads was reported (Table 4.2) for
known high intronic genes (Ameur et al., 2011). Each gene examined had a 52 to
100% intronic mapping percentage.
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Figure 4.3. Comparison of read type for paired reads in white matter, neuron, and
astrocyte samples. The percent of exon (white bar), exon-exon (shaded bar), and intron
(black bar) reads of total paired reads were plotted.

Figure 4.4. Comparison of read type for paired reads in control and ASD white matter
(A) and neuron (B) samples. The percent of exon (white bar), exon-exon (shaded bar),
and intron (black bar) reads of total paired reads were plotted for white matter and
neuron control and ASD samples.
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Table 4.2. Percentage of Intron Reads for Known High Intronic Genes.
Ameur et al. (Ameur et al., 2011) produced a ranking of genes in the adult and fetal
brain that produce the highest amount of intronic reads using RNA-Seq. The top genes
from those lists were examined in our data. The table below contains the mean
percentage of intron reads for each of the genes listed for all white matter, neurons and
astrocyte samples. For white matter and neurons samples, the mean percentage of
intron reads is given for control and ASD subjects separately.
Gene Name
PCDH9
PCDH7
QKI
NRXN1
KCNC2
PID1
KLF7

White Matter
Control
ASD
85.69%
87.56%
93.29%
83.84%
57.90%
62.96%
89.63%
92.92%
72.24%
68.44%
99.84%
99.98%
70.51%
69.28%

Neurons
Control
ASD
91.38%
92.20%
85.18%
87.38%
66.95%
52.15%
86.05%
88.33%
88.93%
56.78%
99.70%
99.70%
64.50%
70.98%

Astrocyte
82.50%
71.70%
69.90%
96.60%
100.00%
100.00%
60.90%

Differentially Expressed Genes. A list of differentially expressed genes (DEGs)
comparing control and ASD donor samples (Table 4.5) was produced for white matter
and neuron samples preparations. The expression level of these genes was
determined by the RPKM (reads per kilobase per million mapped reads) of exon
mapping reads only. Two genes, STX8 and SSR3, were selected for confirmation of
DEGs in the BA24 pyramidal neuron samples. The expression of the two genes was
not found to be different comparing the same control and ASD donors as was used for
the RNA-Seq experiment (Figure 4.6).
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Figure 4.5. Differentially expressed genes in white matter and neuron samples. These
heat maps represent the log2 transformed normalized expression value (RPKM) for
each sample using a Baggerly beta-nominal test analysis. (A) white matter unpaired
analysis (B) white matter paired analysis (C) neuron unpaired analysis (D) neuron
paired analysis
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Figure 4.6. Levels of expression of STX8 and SSR3 in pyramidal neurons of BA24.
Gene expression was measured in laser captured BA24 pyramidal neurons from
typically developing control donors (open symbols) and ASD donors (closed symbols).
Gene expression levels are normalized to GAPDH expression levels. Mean values are
noted by horizontal lines. No statistically significant differences were observed.

Abnormalities in Intron Mapping in ASD. Because the majority of the mapped
pair reads were aligned to intron regions, we examined the possibility that the
percentage of intron reads might be predictive of an underlying pathological process in
ASD. To start with, two genes found to be differentially expressed between control and
ASD subjects using exon mapped reads were compared at the level of mapped introns.
From RNA-Seq data of control and ASD donors, I compared the reads mapped to STX8
and HSD17B12 introns as a fraction of the total reads. Those genes were chosen to
have a comparison of how intron reads mapped for one gene with altered exon
expression in neurons and one with altered exon expression in white matter. The
fraction of reads mapped to STX8 introns was significantly lower in ASD donors in
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neurons but not white matter. In contrast, the fraction of HSD17B12 reads mapping to
intronic regions was lower in white matter but not neurons comparing control and ASD
donors (Figure 4.7).

Figure 4.7. Comparison of intron reads for STX8 and HSD17B12 between control and
ASD subject samples for neuron and white matter sample preparations. The ratio of
intron reads to total reads for each gene is plotted for control (open symbols) and ASD
(closed symbols) subjects for neurons and white matter samples. Statistical
significance is noted in graph.

Discussion
The primary goal of this study was to establish the feasibility of using RNA-Seq to
examine gene expression in brains cells captured by LCM. Three different LCM
sampling methods were performed to determine which was suitable for this type of
analysis. Overall, the quality of the sequencing data was high with a PHRED score that
exceeded 35 and over 75% of all reads mapping to the reference genome for all sample
preparation types (white matter, neuron, and astrocyte). There were also no observable
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differences between samples from control and ASD subject in terms of the quality of the
RNA-Seq data generated. Once the ability to sequence the prepared libraries and map
those reads to a reference genome was confirmed, the next step was to determine what
the mapped reads represented.
A secondary goal of this study was to utilize LCM/RNA-Seq to compare the gene
expression profiles of brain neurons and glia from typically developing control and ASD
donors. One obvious and major problem with this part of the study was a small sample
size, and hence the low power of the statistical analyses of the comparison of the two
study groups. During the sample preparation stage, there were more subject samples
than those reflected in the final analysis above. However, due to various reasons such
as poor RIN quality, low mapping rate, and low RNA-Seq library yield, samples from
some subjects were eliminated prior to RNA-Seq analysis. For the few control-ASD
pairs that we were able to analyze, we generated a list of differentially expressed genes
for the RNA-Seq data for neuron and white matter samples (Figure 4.5). However, only
two of the three pairs matched the RNA-Seq data by showing greater levels of STX8
expression in ASD subjects compared to the controls using PCR confirmation (Figure
4.6). The small sample size could have been a cause for the inability to confirm the
RNA-Seq finding with PCR. We are currently working to prepare more RNA-Seq
libraries from additional paired subjects for analysis. For now, we assume that our
inability to fully confirm existing RNA-Seq data is related to the small group sizes.
Within all the sample preparation types, a high percentage of intron mapping was
observed. This is consistent with other RNA-Seq studies performed on brain tissue
samples (Ameur et al., 2011; Kapranov et al., 2010). The high amount of intron reads
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does not affect our ability to determine differential expressed genes since the RPKM or
expression value is determined by exon mapping reads only. However, these intron
reads and the differences therein between control and ASD samples suggest that other
forms of transcriptional regulation in the brain may differentiate ASD from control
subjects. There is evidence that genes involved in neuronal plasticity and synaptic
regulation are stored in an unprocessed RNA form within cell (Ameur et al., 2011). This
allows for another level of gene expression regulation within the dynamic cellular
environment of the brain. Based on the results shown in Figure 4.7, the ratio of intron
reads to total reads is significantly difference between control and ASD samples. This
could reflect that the regulatory control in processing pre-mRNA to fully mature mRNA
could be altered in ASD. This hypothesis will need to be confirmed using intron specific
primers.
One of the disadvantages to using LCM collected samples is the small amount of
material that can be obtained. When coupling LCM with the use of postmortem brain
tissue, restrictions such as cost, time, and limited availability of tissue does not allow for
the collection of sufficient amounts of input materials needed for many downstream
applications. Due to the limited amount of sample that can be obtained from LCM,
sample amplification is an unavoidable preparation step in the transcriptional analysis.
The amplification step in sample preparation is a sensitive process that could introduce
experimental artifact if not performed correctly or tailored to specific biological samples.
Experiments were performed using both commercially available kits and LCM
specialized protocols to determine the most effective and reliable method for sample
amplification. The first strand synthesis step of RNA amplification is crucial since it
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creates the basic template for amplification. Most methods are based on a 3’ bias
selection for this step of amplification. This selection technique is beneficial for reducing
other RNA species such as rRNA and tRNA from the sample prior to mass
amplification. This selection reduces potential bias toward more abundant RNAs since
mRNA and non-coding RNA are significantly outnumbered by other RNA species in the
samples. For samples collected from LCM, this 3’ bias could reduce fidelity in
amplification. Using frozen human tissue for these studies means that optimal RNA
quality is never achieved because of decay that occurs during the brain collection
process. A 3’ bias selection could inadvertently exclude mRNAs that are susceptible to
3’ degradation. Unlike other kits available on the market, the NuGEN amplification kits
create a first strand using 3’ and random primers giving better transcriptome coverage
and reducing potential bias from degradation effects. This feature makes the kits ideal
for LCM samples based on its tolerance for less than optimal RNA integrity and a small
RNA input requirement of 100 picograms. However, the lack of ribosomal depletion or
mRNA selection could have inadvertently biased our samples to pre-mRNA or intron
containing transcripts. Intron spanning regions are larger than exon regions and would
be more abundantly represented in the samples. It is still unclear if our samples
produced enough exon based reads to truly reflect transcriptional changes at the
mature mRNA level. Our samples might illustrate the regulation occurring between
transcription and the finally mRNA product. More confirmation of the RNA-Seq data
and more samples will be needed in order to fully answer this question.
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Conclusion
When developing this method, efforts were made to circumvent the potential
pitfalls associated with analyzing LCM samples. We were able to control for the
limitations of these samples by selecting protocols suitable for sample type and putting
in controls for the biological variances of human studies. There is still more work to be
done to produce a full-scale analysis of transcription regulation underlying ASD brain
pathology. In order to achieve that goal, there must first be a characterization of the
type of transcriptional regulation reflected in our data whether it is exon or intron based.
The data presented above suggest potential regulation at the pre-mRNA level in
addition to that at the mature mRNA level. Further examination of intron based changes
could reveal yet unknown transcriptional dysregulation associated with ASD brain
pathology.
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CHAPTER 5
SUMMARY AND CONCLUSIONS

The data in this dissertation provide evidence that autism pathology exists at the
level of white matter astrocytes and glutamatergic pyramidal neurons in the ACC. Many
past studies have shown gross anatomical differences between typically developing
brains and those of autism patients. However, those findings have not lead to an
understanding of the underlying cause of ASD brain abnormalities. By examining the
pathology of autism and the cellular and molecular level as performed here, a more
cogent understanding of autism neuropathology can be established. It is anticipated
that with greater knowledge of the pathological process of autism, a strategy for
developing biologically therapeutic interventions will be possible.
The studies present several different methods for the examination of ASD brain
pathology at a cellular level. Chapter 2 used a combination of protein and gene
expression analysis to determine the potential role of glial cell populations in ASD brain
pathology. For a long time glial cell populations were thought of as merely support
cells. In recent years glia have been found to play major roles in maintaining brain
homeostasis. Glial dysfunction can be observed in a variety of brain pathologies. The
study presented here revealed an increase in the glial marker GFAP in the ASD brain.
This alteration was very specific to brain region (BA24 as opposed to BA10) and matter
type (white matter as opposed to gray matter). This type of regional specificity of
pathology reinforced the need to further explore ASD brain pathology at a higher
anatomical resolution. For example, the abnormality of GFAP protein in ASD could
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have gone undetected using a sample that contained both white and gray matters as
typically are used in other postmortem ASD studies.
Chapter 3 explored pathology and a remarkably greater level of resolution, i.e. in
two cell populations, neurons and astrocytes, from a discrete area of the brain (ACC).
This work focused on key genes in the glutamate pathway because the type of neuron
studied (pyramidal neuron) is known to use the neurotransmitter glutamate. Imbalances
in this neurochemical pathway are theorized to contribute to ASD brain pathology and
ASD behaviors. The genes investigated encode receptors, transmitters, and synaptic
proteins. All of these proteins play a direct role in the release and termination of
glutamate signaling. Gene expression differences were found comparing control and
ASD subjects in ACC pyramidal neurons for genes such as NTRK2 and GRIP1, but no
changes were found for any genes in the astrocyte population. These neuronal gene
changes were specific to BA24 neurons and were not found in BA10 neurons from the
same subjects. These findings again speak to the specificity of cellular ASD pathology
and provide a molecular basis for the excitatory and inhibitory imbalance that has been
theorized to occur in ASD brain based on imaging studies. Collectively, the genes
found to be reduced in ASD provided evidence that excess receptor signaling could be
creating neuronal dysfunction. This type of dysfunction generally increases intercellular
signaling pathways to the point that cell death occurs. The death of excitatory neurons
would certainly change the overall excitatory and inhibitory balance. In future studies,
we will focus on inhibitory cell populations to determine expression changes that might
affect the overall balance of this system. These expression changes could help reveal
the dysfunctional or compensatory mechanisms that characterize the brain pathology of
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ASD.
Chapter 4 outlined the development of a protocol for a more in-depth analysis of
transcription regulation in a disease state using laser captured samples. While Chapter
3 took a very targeted approach to exploring specific gene expressions in the ASD
brain, work in Chapter 4 was designed to interrogate all gene expressions within a cell
population of the ACC. This approach is often considered “unbiased” in that it is not
assuming any particular abnormality but examining all possible abnormalities in gene
expression. In terms of bioinformatics the data produced achieved high quality scores
and mapping rates. However, the protocol used to amplify the small amount of RNA
template could have introduced a possible bias towards more abundant fragments such
as the intron portions of pre-mRNAs. This is evident in the high number of intronic
mapped reads. More analysis will need to be performed to determine the transcription
information provided from these data.
Overall, this research identified specific cellular pathologies that could contribute
to ASD brain pathology and ultimately to ASD behaviors. In addition, preliminary data
suggest that the it is possible to combine the methods of RNA-Seq and laser capture
microdissection to perform whole transcriptome analysis of single cell types from the
human brain, an approached that has not been previously achieved to date. The
methods herein dramatically increase the anatomical and cellular resolution of the study
of brain pathologies and greatly expand the amount of data that can be derived from
postmortem brain samples. Ultimately these approaches provide a unique opportunity
for the development of new theories regarding the pathogenesis and pathology of ASD.
Future studies will include a deeper analysis of the pathways associated with the
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differential expressed proteins and genes found in Chapters 2 and 3 as well as
additional validation of the method developed in Chapter 4.
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APPENDICES
APPENDIX A: Abbreviations and Definitions
Abbreviation
ABCB6
ACC
AD
ADI-R
ASD
AUP1
BA10
BA24
BDNF
CDC
CLIC4
Ct
DEG
DSM-IV
DSM-V
DTI
EEG
ERK
FDA
GAPDH
GFAP
GM
GRIA1
GRIK2
GRIN1
GRIN2A
GRIN2B
GRIN2C
GRIN2D
GRIP1
GRM5
GRM8
HSD17B12

Definition
ATP-binding cassette sub-family B member 6
Anterior cingulate cortex
Alzheimer Disease
Autism Diagnostic Interview Revised
Autism spectrum disorder
Ancient ubiquitous protein
Brodmann area 10
Brodmann area 24
Brain derived neurotrophic factor
Centers for Disease Control
Chloride intracellular channel 4
Cycle threshold
Differentially expressed genes
Diagnostic and Statistical Manual of Mental Disorders IV
Diagnostic and Statistical Manual of Mental Disorders V
Diffusion tensor imaging
Electroencephalography
Extracellular signal-regulated kinases
Food and Drug Administration
Glyceraldehyde 3-phosphate dehydrogenase
Glial fibrillary acidic protein
Gray matter
Ionotropic glutamate receptor AMPA1
Ionotropic glutamate receptor kainate 2
NR1; Ionotropic glutamate receptor NMDA 1
NR2A; Ionotropic glutamate receptor NMDA 2A
NR2B; Ionotropic glutamate receptor NMDA 2B
NR2C; Ionotropic glutamate receptor NMDA 2C
NR2D; Ionotropic glutamate receptor NMDA 2D
Glutamate receptor interacting protein
mGluR5; Metabotropic glutamate receptor 5
mGluR8; Metabotropic glutamate receptor 8
Hydroxysteriod 17-beta dehydrogenase 12
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IR
ISG15
KIAA0930
KO
LCM
MAPK
MCCC1
MMR
MOG
MTI
NICHD
NLGN
NT-3
NT-4/5
NTRK2
PCR
PDD-NOS
PET
PI3
PMI
PPP2CB
PTEN
Ribo18S
RIN
RPKM
RT-qPCR
SLC17A7
SLC1A1
SLC1A2
SLC1A3
SLC35A5
SPECT
SSR3
SSRI
STX8
TATA

Immunoreactivity
Interferon, Alpha-Inducible Protein
Uncharateristized protein C22orf9
Knock out
Laser capture microdissection
Mitogen-activated protein kinase
3-methylcrotonyl-CoA carboxylase
measles-mumps-rubella vaccine
Myelin oligodendrocyte glycoprotein
Magnetization transfer imaging
National Institutes for Child Health and Development
Neuroligin
Neurotrophin-3
Neurotrophin-4/5
Neurotrophic tyrosine kinase, receptor, type 2
Polymerase chain reaction
Pervasive developmental disorder-not otherwise specified
Positron emission tomography
Phosphoinositide 3-kinase
Postmortem interval
Protein phosphatase 2, catalytic subunit, beta isozyme
Phosphatase and tensin homolog
18S ribosomal RNA
RNA integrity number
Reads Per Kilobase per Million mapped reads
Reverse transcription real-time polymerase chain reaction
vGluT; vesicular glutamate transporter
EAAT3; Neuronal/Epithelial High Affinity Glutamate
Transporter, Member 1
EAAT2; Glial High Affinity Glutamate Transporter,
member 2
EAAT1; Glial High Affinity Glutamate Transporter,
member 3
Sugar Transport Protein
Single-photon emission computed tomography
Signal sequence receptor, gamma
Selective serotonin reuptake inhibitors
Syntaxin 8
TATA box
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TBP
TMEM9
TrkB
WM

TATA binding protein
Transmembrane protein 9
Tryosine kinase B
White matter
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APPENDIX B. Primer Sequences of Target and Reference Genes
Target or
Reference

Genbank
Accession
Number

AQP4

NM_001650
NM_004028

BDNF

NM_170735
NM_170732
NM_170731
NM_001709
NM_170733
NM_170734

GAPDH

Primer
Sequence
(f) TCCAAACGGACTGATGTCACTGGCT
(r) CAAAGGATCGGGCGGGATTCATGC
(f)
AGAGCCCTGTATCAACCCAGAAACACC
(r) GCAATGCCAACTCCACATAGCCTCC

PCR
Product
Size (bp)
118

112

NM_002046

(f) TGCACCACCAACTGCTTAGC
(r) GGCATGGACTGTGGTCATGAG

87

NM_002055

(f) AAGCTGCTAGAGGGCGAGGAGAAC
(r) TGACACAGACTTGGTGTCCAGGCT

99

GRIA1

NM_001200

(f) GTGCGCAGCTTCCACCATGAA
(r) CTGAGGTGATAAACTCCTCCGTGGG

122

GRIK2

NM_000830
NM_175611

(f) ATTGACTCCAAAGGTTACGGAGTGGG
(r) GCAGCTTCCCTTCTTCTTGGAGTTGA

100

NM_000832
NM_021569
NM_007327

(f) CCTGGAAGCAGAACGTCTCCCTGT
(r) TGCTGCGCGAGTCACATTCCTGAT

108

GRIN2A

NM_001134407
NM_000833
NM_001134408

(f) TCGACCTGGCCTTGCTTCAGTTTGT
(r) GCTGGCTGCTCATCACCTCGTTCTT

111

GRIN2B

NM_000834

(f) CCTCATCACCTTCATCTGCG
(r) CATGGATGCAGCTGTAGATACC

125

GRIN2C

NM_000835

(f) TGGTGGCCATCACCGTCTTCAT
(r) CCACACGGACTTGCCGATAGTGA

116

GRIN2D

NM_000836

(f) CTTCGTGGAGACCGGCATCAGCGTC
(r) ACGAACATCATCACCCACACGGCGG

108

GFAP

GRIN1
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GRIP1

NM_021150
NM_001178074

(f) GCCACAGAAACTCTCTCTTCTCCACC
(r) CACTCTGTCTCCAATCTGTAGCACCC

96

GRM5a

NM_000842

(f) GCCAGCAGATCCAGCAGCCTAGTCA
(r) TCATTCTGGGCCCACGTGACGGATT

101

GRM5b

NM_000842
NM_001143831

Not available, purchased from Qiagen

GRM8

NM_000845
NM_001127323
NM_001127326
NR_028041

Not available-Purchased from Qiagen

78

MOG

NM_002433.3
NM_206809.2

(f) CCTGCTGGAAGATAACCCTGTTTG
(r) CACTCAGAAGGGATTTCGTAGCTC

134

NM_006180
NM_001007097
NM_001018064
NM_001018065
NM_001018066

(f) TGTAGTGTGGCAGGTGATCCGGT
(r) GGAGCCCTGTGTGTGGCTTGTTT

96

RNA18S1

NR_003286

(f) GTAACCCGTTGAACCCCATT
(r) CCATCCAATCGGTAGTAGCG

131

SLC1A1a

NM_004170

Not available, purchased from Qiagen

110

SLC1A1b

NM_004170

(f) CCTGAAGTCAGTACGGTGGATGCC
(r) GGGAGGCTTCACTTCTTCACGCTT

117

SLC1A3

NM_004172

(f) TGCAAGCACTCATCACCGCTCTGGG
(r) ACGCGCTTGTCCACGCCATTGTTCT

100

SSR3

NM_007107

Not available, purchased from Qiagen

109

STX8

NM_004683
NR_033656

Not available, purchased from Qiagen

105

TATA

NM_003194

(f) CACTTCGTGCCCGAAACGCCGAAT
(r) ATCAGTGCCGTGGTTCGTGGCTCT

88

UBC

NM_021009

(f) ATTTGGGTCGCGGTTCTTG
(r) TGCCTTGACATTCTCGATGGT

133

NTRK2
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VGlut1

NM_020309

(f) TCGGAGAGAGCGCGAAACTCAT
(r) TGGCCACGATGATGGCATAGACT
a

b

Denotes use in RT-PCR experiments
Denotes use in Endpoint-PCR experiments
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